Patent Publication Number: US-2015087812-A1

Title: Human Autotaxin Antibodies and Methods of Use

Description:
FIELD OF THE INVENTION 
     The present invention relates to a human antibody capable of binding directly to the lysophospholipase, autotaxin, and in one aspect, neutralizing the catalytic activity of the enzyme as evidenced by the lack of production of lysophosphatidic acid (LPA), and methods of use to treat disease states related to unwanted autotaxin catalytic activity. 
     BACKGROUND OF THE INVENTION 
     Autotaxin (ATX), also known as ectonucleotide pyrophosphatases/phosphodiesterases 2 (ENPP2), is a secreted lysophospholipase D (E.C. 3.1.4.39). In mammals, the enzyme produces phospholipid lysophosphatidic acid (LPA) from lysophosphatidylcholine (LPC). It was first discovered as an autocrine motility factor released by a human melanoma A2058 cell line (Stracke et al., J Biol Chem 267: 2524-2529, 1992). Subsequent independent studies identified ATX as the extracellular enzyme responsible for the generation of LPA from LPC (Tokumura et al., J Biol Chem 277:39436-39442, 2002; Umezu-Goto et al., J Cell Biol 158: 227-233, 2002). ATX may also catalyze the conversion of sphingosylphosphorylcholine (lysophosphingomyelin) to sphingosine-1-phosphate (S1P), which is also a modulator of cell motility. 
     ATX is a secreted 100 KDa glycoprotein comprising two cysteine-rich N-terminal somatomedin B like domains (SMB1 and SMB2), a central phosphodiesterase domain (catalytic domain) and a C-terminal nuclease-like domain. Three isoforms of ATX have been reported in both human and mouse as a result of alternatively spliced autotaxin transcripts. Human isoform alpha lacks exon 21 and has 915 amino acids, and it is identical to the originally discovered ATX from human melanoma A2058 cells; isoform beta lacks exon 12 and 21 and has 863 amino acids; isoform gamma lacks exon 12 and has 889 amino acids. All three isoforms are identical from amino acid residues 1-324 which includes the catalytic (201-214) and substrate binding domains (244-255). The isoforms of ATX are expressed differentially. Based on quantitative PCR studies, ATX expression is limited to peripheral tissues as the beta isoform; the gamma isoform is mainly expressed in the brain in both mouse and human (Giganti, et al., J Biol Chem 283: 7776-7789, 2008). All three recombinant isoforms catalyze LPC conversion to LPA, with the beta isoform having the strongest hydrolytic activity, followed by the gamma isoform, then the alpha isoform, which has the least stability and activity (Giganti, et al., J Biol Chem 283: 7776-7789, 2008). 
     The roles of ATX, LPA and S1P in disease pathology, especially, cancer have become an area of intense scientific interest. The cancer promoting properties of ATX have been ascribed to the growth-factor-like responses evoked by LPA in the vast majority of tested cell types (Lee et al., J Biol Chem 271 (40): 24408-12, 1996; Hama et al., J Biol Chem 279: 17634-17639, 2004). LPA and other lysophospholipids signal through specific G-protein coupled receptors formerly known as Edg (endothelial differentiation gene) receptors. LPA receptors Edg-2, Edg-4 and Edg-7 are now also termed as LPA 1 , LPA 2  and LPA 3  receptor (Ishii et al., Annu. Rev. Biochem. 73 (2004), 321-354). Additional LPA receptors as well as receptors for sphingosine-derived ATX catabolite sphingosine-1-phosphate (S1P) S1P1 to 5, have also been identified. Signaling of these receptors has been linked to important physiological and pathophysiological effects including cell migration, cell survival, proliferation, and neuropathic pain (Choi et al., Ann. Rev. Pharmacol. Toxicol. 50: 157-186, 2010; Tokumura et al., Am. J. Physiol. 267: C204-C210, 1994; Rizza et al., Lab. Invest. 79: 1227-1235, 1999; Inoue et al., Nat. Med. 10: 712-718, 2004). Indeed, overexpression of either ATX or LPA receptors have been shown to promote tumor formation, angiogenesis and metastasis (Liu et al., Cancer Cell 15: 539-550, 2009; Nam et al., Oncogene 19: 241-247, 2000; Taghavi et al. Oncogene 27: 6806-6816; 2008; Yu et al., J. Natl Cancer Inst. 100: 1630-1642, 2008). At the same time, elevated ATX concentrations have been observed in a number of cancerous tissues (Xu et al., Clin. Cancer Res. 1: 1223-1232, 1995; Eder et al., Clin. Cancer Res. 6: 2482-2491, 2000; Xie et al., J Biol Chem 277: 32516-32526, 2002; Yang et al., Am. J. Respir. Cell. Mol. Biol. 21: 216e222, 1999; Yang et al., Clin. Exp. Metastasis 19: 603-608, 2002). These relationships indicate that ATX is an important drug target and reducing the enzymatic activity of ATX could be beneficial for the treatment of cancer. 
     ATX has an essential requirement for divalent metal cations, and activity can be inhibited in the presence of metal chelators, such as EDTA, phenanthrolines, and L-histidine, albeit at millimolar concentrations (Clair et al., Lipids Health Dis., 4:5, 2005). LPA causes end-product inhibition of ATX activity, which led to the search for other LPA analogs that were capable of inhibiting ATX (van Meeteren et al., J Biol. Chem. 280: 21155-21161, 2005). Analogs differing from LPA structurally in the details of the hydrophobic tail, the linker region or in the head group itself have inhibition constants from 100 nM to 1 μM. One such molecule is α-bromomethylene phosphonate LPA (BrP-LPA), a phosphatase resistant LPA analog that inhibits ATX and antagonizes LPA receptors in the micromolar range (Jiang et al., Chem Med Chem 2: 679-690, 2007). Another synthetic inhibitor is [4-(tetradecanoylamino)benzyl]phosphonic acid (S32826), which inhibits ATX with an IC50 in the 10 nM range (Ferry et al., J Pharmacol Exp Ther 327:809-819, 2008). LPA analogs may, however, agonize or antagonize a varying spectrum of LPA receptors and thus may not block all LPA functions. 
     Several monoclonal antibodies have been generated by different groups with full length human ATX or partial ATX peptides (Nakamura et al., Clinica Chimica Acta 388:51-58, 2008; Tanaka et al., FEBS Letters 571: 197-204, 2004; US 2010/0120064A1; WO2011/151461A2), however, no ATX function blocking large biologic molecule, e.g. a monoclonal antibody or fragment, have been reported. 
     SUMMARY OF THE INVENTION 
     The present invention provides monoclonal antibodies capable of binding ATX with high affinity and, in one aspect, blocking the ability of the enzyme to catalyze the production of lysophosphatidic acid (LPA) species from lysophosphatidylcholine. An antibody of the invention is useful as a therapeutic to treat conditions arising from unwanted production of LPA species and the sequelae of biological responses related to binding of LPA to one or more of LPA receptors, now known as LPAR1-6 on cells, tissues, or organs in a host subject. In another aspect of the invention, pairs of ATX binding monoclonal antibodies have been identified that can bind ATX concurrently and, which pairs may also comprise the ability to eliminate ATX from tissues in a host or to neutralize the catalytic activity of ATX. 
     The antibodies were discovered using a human Fab library displayed on the surface of a bacteriophage attached to the coat protein pIX. The human antibody fragments derived from the phage library represent functional antigen binding fragments that can be configured as fully human antibodies or other constructs useful as effective therapeutics and detection reagents for disease associated with unwanted autotaxin level or activity such as in cancer patients. 
     Amino acid sequences of exemplary ATX binding human monoclonal antibody fragments are provided which can be encoded by nucleic acids for expression in a host cell. One aspect of the invention is an isolated antibody reactive with human ATX protein having the antigen binding ability of a monoclonal antibody comprising an antigen binding domain comprising amino acid sequences as set forth at specified positions of a human antibody variable domain region, FR1-CDR1-FR2-CDR2-FR3, as set forth in SEQ ID NOs: 1-3 and 5-8, or are an isolated CDR or CDR regions which can be used to create a functional binding protein having at least one variable regions and further comprising the identified CDR1, CDR2, or CDR3 regions in a heavy or light chain human framework. 
     The isolated variable regions identified as ATX binding regions are represented by SEQ ID NO: 16-48; or an antigen binding domain comprising a CDR with amino acid sequences as set forth in SEQ ID NOs: 49-199 alone or at specified positions as set forth in SEQ ID NOs: 1-3 or 5-8 and variants thereof. In a specific embodiment, the human ATX binding antibody comprises a variable domain comprising a sequence selected from any of the possible VH variants of SEQ ID NO: 200 or the VL variants of 201. 
     In another embodiment of the invention, the monoclonal antibody binding domains used as full length IgG structures, have constant domains derived from human IgG constant domains or specific variants thereof and are used as therapeutic molecules in a pharmaceutical preparation to cause the inactivation of ATX in the body by enhanced elimination or inhibition of the catalytic function of ATX locally or systemically. In another embodiment, the binding domains are configured as antibody fragments for use as a therapeutic molecule capable of binding of ATX. In one aspect of the invention, there is provided a pharmaceutically acceptable formulation, delivery system, or kit or a method of treating conditions related to the activity of ATX comprising one or more of the ATX binding domains of the invention such as but not limited to 16-48 and 49-199, in particular H-CDR3 as represented by SEQ ID NO: 61-103, the L-CDR3 sequence QQSYSTPL (SEQ ID NO: 156) and VH and VL pairs as provided by the sequence variants of SEQ ID NO: 200 and 201, respectively. 
    
    
     
       BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING 
         FIG. 1A-B  shows the germline gene sequences and numbering system used to build the Fab libraries displayed on pIX coat protein, wherein each of the HV domains consist of a variegated FR1-CDR1-FR2-CDR2-FR3 according to SEQ ID NO: 1-3 (1=IGHV1-69, 2=IGHV3-23, and 3=IGHV5-51) followed by a variable length, variegated H-CDR3 region, and a J-region (FR4, SEQ ID NO: 4) (1A); and each of the LV domains consist of a variegated FR1-CDR1-FR2-CDR2-FR3 according to SEQ ID NO: 5-8 (5=IGKV1-39 (012), 6=IGKV3-11 (L6), 7-IGKV3-20 (A27), and 8=IGKV4-1 (B3)) followed by a CDR3 according to SEQ ID NO: 9 which is followed by a J-region (FR4, SEQ ID NO: 10) (1B). IGHV1-69: SEQ ID NO: 202; IGHV3-23: SEQ ID NO: 203; IGHV5-51: SEQ ID NO: 204; IGKV3-20 (A27): SEQ ID NO: 205; IGKV4-1 (B3): SEQ ID NO: 206; IGKV3-11 (L6): SEQ ID NO: 207; IGKV1-39 (012) SEQ ID NO: 208. 
         FIG. 2  is a column graph of showing the relative inhibition of the artificial substrate, FS-3, hydrolysis by human ATX beta isoform (2.5 nM) for 18 MAbs tested at 2.5 microgram per ml and a human IgG1 control Mab. 
         FIG. 3  is a graph showing the concentration dependent inhibition of enzymatic conversion of LPC to LPA by human ATX beta isoform (1.5 nM) using the coupled choline oxidation assay by six neutralizing Mabs and the calculated IC50 for each. The compound S32826 is a small molecule ATX end product analog inhibitor. 
         FIG. 4  is a graph showing the concentration dependent inhibition of enzymatic conversion of LPC to LPA by mouse ATX using the coupled choline oxidation assay by six neutralizing Mabs and the calculated IC50 for each. The compound S32826 is a small molecule ATX end product analog inhibitor. 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as though fully set forth. 
     ABBREVIATIONS 
     ATX=autotaxin; BSA=bovine serum albumin; CDR=complementarity determining region; Fab=fragment antigen-binding; F(ab′)2=structure which is two Fab′ monomers; FR=framework; H=heavy chain; IC50=half maximal inhibitory concentration; Ig=immunoglobulin; L=light chain; LPA=lysophosphatidic acid; LPC=lysophosphocholine; Mab=monoclonal antibody; sphingosylphosphorylcholine=SPC; sphingosine-1-phosphate=S1P; PBS=phosphate buffered saline; VL=Variable light chain; VH=Variable heavy chain 
     DEFINITIONS 
     As used herein, an “antibody” includes whole antibodies and any antigen binding fragment or a single chain thereof. Thus, the antibody includes any protein or peptide containing molecule that comprises at least a portion of an immunoglobulin molecule, such as but not limited to, at least one complementarity determining region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain variable region, a heavy chain or light chain constant region, a framework (FR) region, or any portion thereof, or at least one portion of a binding protein, which can be incorporated into an antibody of the present invention. The term “antibody” is further intended to encompass antibodies, digestion fragments, specified portions and variants thereof, including antibody mimetics or comprising portions of antibodies that mimic the structure and/or function of an antibody or a specified fragment or portion thereof, including single chain and single domain antibodies and fragments thereof. Functional fragments include antigen-binding fragments to a preselected target. Examples of binding fragments encompassed within the term “antigen binding portion” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH, domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH, domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (I 988) Science 242:423-426, and Huston et al. (1988) Proc. Natl. Acad Sci. USA 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term “antigen-binding portion” of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies. Conversely, libraries of scFv constructs can be used to screen for antigen binding capability and then, using conventional techniques, spliced to other DNA encoding human germline gene sequences. One example of such a library is the “HuCAL: Human Combinatorial Antibody Library” (Knappik, A. et al. J Mol Biol (2000) 296(1):57-86). 
     The term “CDR” refers to the complementarity determining region or hypervariable region amino acid residues of an antibody that participate in or are responsible for antigen-specific binding. The hypervariable regions or CDRs of the human IgG subtype of antibody comprise amino acid residues from residues 24-34 (L-CDR1), 50-56 (L-CDR2) and 89-97 (L-CDR3) in the light chain variable domain and 31-35 (H-CDR1), 50-65 (H-CDR2) and 95-102 (H-CDR3) in the heavy chain variable domain as described by Kabat et al. (1991 Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md.) and/or those residues from a hypervariable loop (i.e., residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) or the current H2 Chothia definition of 52-57, and 96-101 (H3) in the heavy chain variable domain as described by (Chothia and Lesk, J. Mol. Biol. 196: 901-917 (1987)). Chothia and Lesk refer to structurally conserved HVs as “canonical structures.” Framework or FR1-4 residues are those variable domain residues other than and bracketing the hypervariable regions. The numbering system of Chothia and Lesk takes into account differences in the number of residues in a loop by showing the expansion at specified residues denoted by the small letter notations, e.g., 30a, 30b, 30c, etc. More recently, a universal numbering system has been developed and widely adopted, international ImMunoGeneTics information System® (IMGT) (LaFranc, et al. 2005. Nucl Acids Res. 33:D593-D597). 
     Herein, the CDRs are referred to in terms of both the amino acid sequence and the location within the light or heavy chain by sequential numbering. As the “location” of the CDRs within the structure of the immunoglobulin variable domain is conserved between species and present in structures called loops, by using numbering systems that align variable domain sequences according to structural features, e.g. the numbering system of Kabat; CDR and framework residues and are readily identified. This information is used in grafting and replacement of CDR residues from immunoglobulins of one species into an acceptor framework from, typically, a human antibody ( FIG. 1 ). 
     The term “maturation” is applied to directed changes in an antibody variable region for the purpose of altering the properties of the polypeptide. As is known in the art and described herein, a large number of positions in the V-region sequences that can impact recognition of antigen. In nature, antibodies achieve high affinity and specificity by the progressive process of somatic mutation. This process can be imitated in vitro to permit parallel selection and targeted variation while maintaining the sequence integrity of each antibody chain such that they reflect the species, in the present case, a human, antibody, while enhancing affinity or a biophysical parameter such as solubility or resistance to oxidation. The process of making directed changes or “maturation” is typically performed at the level of the coding sequence and can be achieved by creating sublibraries for selection of the enhanced property. 
     As used herein “ATX” refers to an autotaxin polypeptide or a gene or polynucleotide comprising a coding sequence encoding the ATX polypeptide. ATX is also known as ectonucleotide pyrophosphatases/phosphodiesterases 2 (ENPP2), NPP2, ATX-X, PDNP2, LysoPLD, PD-IALPHA. ATX is a secreted lysophospholipase D (E.C. 3.1.4.39) a phospholipase, which catalyzes production of lysophosphatidic acid (LPA) in extracellular fluids but also functions as a phosphodiesterase, which cleaves phosphodiester bonds at the 5′ end of oligonucleotides (EC 3.6.1.9). Human ATX is the product of the human ATX gene (NCBI Gene 5168) located on human chromosome 8q24.1. Three isoforms of ATX have been reported in human from alternatively trans-splicing. Human isoforms including signal peptide and propeptide are given here as alpha (SEQ ID NO: 12, UnitProt Q13822-2, or NCBI# NP006200.3) with 915 amino acids; beta (SEQ ID NO: 11, UnitProt Q13822, or NCBI# NP001035181.1) with 863 amino acids; and gamma (SEQ ID NO: 13, UnitProt Q13822-3, or NCBI# NP001124335.1) with 888 amino acids. The signal and propeptide regions are identical in each isoform where the signal peptide spans residues 1-27 and furin cleavage removes 28-35 (predicted) or 28-48 (Murata et al., JBC 269:48 page 30479), respectively. Isoform alpha has exon 21 deleted and expresses the exon 12 in which a cleavage site is present, leading to a rapid catabolism of the isoform and inactivation of the cleaved protein; Isoform beta has two exons deleted (12 and 21), and isoform gamma has only exon 12 deleted. The ATX sequence is conserved among a number of species. Recombinant mouse ATX beta isoform (UnitProt Q9R1E6, SEQ ID NO: 14) has 94% identity with the human beta isoform over the entire proprotein, 96% in the catalytic domain 201-255), and 100% in the substrate binding region (201-255 of Q13822, SEQ ID NO: 11). 
     The term “epitope” means a protein determinant capable of specific binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules, such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. 
     As used herein, K D  refers to the dissociation constant, specifically, the antibody K D  for a predetermined antigen, and is a measure of affinity of the antibody for a specific target. High affinity antibodies have a K D  of 10 −8  M or less, more preferably 10 −9  M or less and even more preferably 10 −10  M or less, for a predetermined antigen. The reciprocal of K D  is K A , the association constant. The term “k dis ” or “k 2 ,” or “k d ” as used herein, is intended to refer to the dissociation rate of a particular antibody-antigen interaction. The “K D ” is the ratio of the rate of dissociation (k 2 ), also called the “off-rate (k off )” to the rate of association rate (k 1 ) or “on-rate (k on ).” Thus, K D  equals k 2 /k 1  or k off /k on  and is expressed as a molar concentration (M). It follows that the smaller the K D , the stronger the binding. Thus, a K D  of 10 −6 M (or 1 μM) indicates weak binding compared to 10 −9 M (or 1 nM). 
     As used herein, LPA, indicates any of the lysophosphatidic acids derived from a corresponding lysophosphoroylcholine (LPC). LPC is produced from phosphatidylcholine by the action of an intracellular or extracellular phospholipase (for example, phospholipase A1 or phospholipase A2) hydrolyzing the acyl chain from either position of the glycerol moiety. As the fatty acyl chain and attachment site (sn-1 or sn-2) to the glycerol backbone may vary, there are a number of possible species. LPA molecular species with different acyl chain lengths and saturation are naturally occurring, including 1-palmitoyl (16:0), 1-palmitoleoyl (16:1), 1-stearoyl (18:0), 1-oleoyl (18:1), 1-linoleoyl (18:2), and 1-arachidonyl (20:4) LPA. In addition, infrequently occurring LPA, such as minor alkyl LPA has biological activities similar to acyl LPA. 
     The terms “monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. The term also includes “recombinant antibody” and “recombinant monoclonal antibody” as all antibodies are prepared, expressed, created or isolated by recombinant means, such as (a) antibodies isolated from an animal or a hybridoma prepared by the fusion of antibody secreting animal cells and an fusion partner, (b) antibodies isolated from a host cell transformed to express the antibody, e.g., from a transfectoma, (c) antibodies isolated from a recombinant, combinatorial human or other species antibody library, and (d) antibodies prepared, expressed, created or isolated by any other means that involve splicing of immunoglobulin gene sequences to other DNA sequences. An “isolated antibody,” as used herein, is intended to refer to an antibody which is substantially free of other antibodies having different antigenic specificities. An isolated antibody that specifically binds to an epitope, isoform or variant of human ATX may, however, have cross-reactivity to other related antigens, e.g., from other species (e.g., ATX species homologs). Moreover, an isolated antibody may be substantially free of other cellular material and/or chemicals. In one embodiment of the invention, a combination of “isolated” monoclonal antibodies having different specificities are combined in a well defined composition. 
     As used herein, “specific binding,” “immunospecific binding” and “binds immunospecifically” refers to antibody binding to a predetermined antigen. Typically, the antibody binds with a dissociation constant (K D ) of 10 −7 M or less, and binds to the predetermined antigen with a K D  that is at least twofold less than its K D  for binding to a non-specific antigen (e.g., BSA, casein, or any other specified polypeptide) other than the predetermined antigen. The phrases “an antibody recognizing an antigen” and “an antibody specific for an antigen” are used interchangeably herein with the term “an antibody which binds specifically to an antigen.” As used herein “highly specific” binding means that the relative K D  of the antibody for the specific target epitope is at least 10-fold less than the K D  for binding that antibody to other ligands. 
     As used herein, “type” refers to the antibody class (e.g., IgA, IgE, IgM or IgG) that is encoded by heavy chain constant region genes. Some antibody classes further encompass subclasses or “isotypes” which are also encoded by the heavy chain constant regions (e.g., IgG1, IgG2, IgG3 and IgG4). Antibodies may be further decorated by oligosaccharides linked to the protein at specific residues within the constant region domains which further enhance biological functions of the antibody. For example, in human antibody isotypes IgG1, IgG3 and to a lesser extent, IgG2, display effector functions as do murine IgG2a antibodies. 
     By “effector” functions or “effector positive” is meant that the antibody comprises domains distinct from the antigen specific binding domains capable of interacting with receptors or other blood components such as complement, leading to, for example, the recruitment of macrophages and events leading to destruction of cells bound by the antigen binding domains of the antibody. Antibodies have several effector functions mediated by binding of effector molecules. For example, binding of the C1 component of complement to antibodies activates the complement system. Activation of complement is important in the opsonisation and lysis of cell pathogens. The activation of complement stimulates the inflammatory response and may also be involved in autoimmune hypersensitivity. Further, antibodies bind to cells via the Fc region, with a Fc receptor site on the antibody Fc region binding to a Fc receptor (FcR) on a cell. There are a number of Fc receptors which are specific for different classes of antibody, including IgG (gamma receptors), IgE (eta receptors), IgA (alpha receptors) and IgM (mu receptors). Binding of antibody to Fc receptors on cell surfaces triggers a number of important and diverse biological responses including engulfment and destruction of antibody-coated particles, clearance of immune complexes, lysis of antibody-coated target cells by killer cells (called antibody-dependent cell-mediated cytotoxicity, or ADCC), release of inflammatory mediators, placental transfer and control of immunoglobulin production. 
     The term “polypeptide” means a molecule that comprises amino acid residues linked by a peptide bond to form a polypeptide. Small polypeptides of less than 50 amino acids may be referred to as “peptides.” Polypeptides may also be referred as “proteins.” 
     Overview 
     The present invention provides isolated Mabs capable of binding and neutralizing the biological activity of mammalian ATX, especially human ATX, and other ATX molecules having the activity of producing LPA from LCA and where the active site includes the consensus sequence as represented by residues 201 to 244 of SEQ ID NO: 11-13 having a Tyr at position 210. 
     Therefore, the present invention is directed toward the identification of human derived ATX-binding Mabs capable of binding to enzymatically active ATX, and optionally, inhibiting downstream biologic activity resulting from LPA production and biological activity resulting from LPA binding to LPAR, such as LPAR1-6. 
     1. Composition of an Antibody of the Invention 
     An ATX-binding antibody of the invention is an antibody that binds enzymatically active forms of ATX and, optionally, inhibits, blocks, or interferes with at least one ATX activity or ATX catalytic end product binding, in vitro, in situ and/or in vivo and does not promote, stimulate, induce, or agonize ATX activity. A suitable ATX-binding antibody, specified portion, or variant can also, optionally, affect at least one ATX activity or end product function, such as but not limited to; RNA, DNA or protein synthesis; protein release; cell activation, proliferation or differentiation; antibody secretion; LPA-receptor signaling; ATX cleavage; ATX binding, ATX induction, synthesis or secretion. 
     The present invention is based upon the discovery of anti-human ATX monoclonal antibodies capable of binding human and mouse ATX. Antibody binding domains in the form of a Fab library displayed on filamentous phage particles linked to the pIX coat protein (see WO29085462A1 and further described herein below) were selected for the ability to bind ATX. Once converted to full Mabs, a competition assay identified those paired VL-VH that, when bound to ATX, prevented other ATX binding Mabs from binding ATX. Alternatively, specified ATX-binding Mabs block the catalytic activity of ATX, such as the conversion of lysophosphatidylcholine to lysophosphatidic acid (LPA) and choline. The ATX-binding antibodies described herein recognize at least two distinct regions on the active form of human ATX protein, indicating the additional discovery of multiple sites on ATX suitable for the ATX binding of antibodies or other compounds with similar function blocking capabilities. Thus, expression and purification of the antibody binding domains provided herein as amino acid sequences further provides the means for selection of novel molecules exhibiting ATX-neutralizing activity. 
     One embodiment of the invention is an isolated monoclonal antibody that specifically binds to isolated, catalytically active, human autotaxin (ATX) protein with a K D  of less than 5×10 −8  M as measured by surface plasmon resonance (SPR). 
     In some embodiments described herein, the anti-human ATX antibody reduces lysophospholipase D activity of ATX as measured by the conversion of lysophosphatidylcholine to lysophosphatidic acid and choline. 
     In some embodiments described herein, the anti-human ATX antibody has a binding region comprising a light chain variable (VL) or heavy chain variable (VH) region comprising the amino acid sequence as shown in SEQ ID NO: 16-48 or 200 or 201; and which antibody or binding portion thereof immuno specifically binds ATX. In some embodiments described herein, the anti-human ATX antibody comprises a heavy chain comprising variants as specified in SEQ ID NO: 200 or an antigen binding portion thereof, binds to human ATX protein and, additionally, has the specified functional properties of antibodies of the invention, such as: 
     binds human ATX with a K D  of less than 10 nM,
 
inhibits the conversion of LPC to LPA and choline in the presence of 2.5 nM human ATX when present at 2.5 ug/ml by at least 20% of the level in the presence of a non-specific IgG 1,
 
inhibits the conversion of LPC to LPA with an IC50 of less than 1.0 μM, and
 
is unable to bind to ATX when one of Mabs B6, B8, B13 or B14 is bound to ATX or binds ATX when one of Mabs B10, B15, or B16 is bound to ATX.
 
     In some embodiments described herein, the structural features of the antibodies exhibiting some or all of the above referenced biological activity as described herein and, in particular, the Mabs designated as B6, B8, B13, B14 and B18 binding domains, are used to create structurally related human anti-ATX antibodies that retain at least one functional property of the antibodies of the invention, such as binding to ATX with a K D  of less than 10 nM (less than 10 −8  M). More specifically, one or more CDR regions of B6, B8, B13, B14 and B18 (SEQ ID NO: 49, 53, 54, 61-65 and 104-106, 139, 140, and 155 or 156) can be combined recombinantly with known human framework regions and to create additional, recombinantly-engineered, human anti-ATX antibodies of the invention. 
     In some embodiments described herein, the anti-ATX antibody comprises a heavy chain complementarity determining region (HCDR) 1 (HCDR1) of amino acid residues 35-49 of SEQ ID NO: 200; a HCDR2 of amino acid residues 64-80 of SEQ ID NO: 200; a HCDR3 of amino acid residues 113-122 of SEQ ID NO: 200; a light chain complementarity determining-region (LCDR) 1 (LCDR1) of amino acid residues 24-34 of SEQ ID NO: 201; a LCDR2 of amino acid residues 50-56 of SEQ ID NO: 201; and a LCDR3 of amino acid residues 89-97 of SEQ ID NO: 201. 
     In some embodiments described herein, the anti-ATX antibody comprises the HCDR1 sequences of SEQ ID NO: 49, the HCDR2 sequences of the sequences selected from the group consisting of SEQ ID NOs: 53 and 54, the HCDR3 sequences selected from the group consisting of SEQ ID NOs: 61-65 and 66, the LCDR1 sequences selected from the group consisting of SEQ ID NOs: 104, 105 and 106, the LCDR2 sequences of the sequences selected from the group consisting of SEQ ID NOs: 139, 140 and 141, and the LCDR3 sequences selected from the group consisting of SEQ ID NOs: 155 and 156. 
     In some embodiments described herein, the anti-ATX antibody comprises a variable heavy (VH) and a variable light (VL) domain, wherein the VH is derived from IGHV1-69 (SEQ ID NO: 202), IGHV3-23 (SEQ ID NO: 203) or IGHV5-51 (SEQ ID NO: 204) human germline genes and the VL is derived from IGKV1-39 (SEQ ID NO: 208), IGKV3-11 (SEQ ID NO: 207) or IGKV3-20 (SEQ ID NO: 205) human germline genes. 
     In some embodiments described herein, the anti-ATX antibody VH is derived from IGHV1-69 (SEQ ID NO: 202) human germline gene and the VL is derived from IGKV1-39 (SEQ ID NO: 208) or IGKV3-20 (SEQ ID NO: 205) human germline gene. 
     In some embodiments described herein, the anti-ATX antibody comprises a consensus sequence for an ATX neutralizing human IGHV1-69 germline derived VH and can be represented as SEQ ID NO: 200: QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLEWMG  GI X 1 P X 2 FG X 3  X 4 NYAQKFQG RVTITADESTSTAYMELSSLRSEDTAVYYCAR  DLYIYG X 5  X 6 DY  wherein  X 1  is I or S, X 2  is I or Y, X 3  is N or T, X 4  is A or T,  X 5  is D or F and X 5  is F or L. 
     In some embodiments described herein, the anti-ATX antibody comprises a consensus sequence for an ATX neutralizing human IGVK1-39 germline derived VL and can be represented as SEQ ID NO: 201: DIQMTQSPSSLSASVGDRVTITC RASQSI X 1  X 2 WLN WYQQKPGKAPKLLIY  X 3 ASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYX 4  X 5 P X 6 T  wherein  X 1    is A, D or G;  X 2    is G or K; and  X 3    is A or T; and  X 4    is S or T;  X 5    is T or Y; and  X 6    is I or L. 
     In one embodiment, the antibodies of the invention have the sequences, including FR1, 2, and/or 3; of IGVH1-69 (SEQ ID NO: 1); IGHV3-23 (SEQ IN NO: 2); or of IGVH5-51 (SEQ ID NO: 3); wherein one or more residues from CDRs selected from the group consisting of SEQ ID NO: 49-199 are present in the CDR position of SEQ ID NO: 1-3, while still retaining the ability of the antibody to bind ATX (e.g., conservative substitutions). Accordingly, in another embodiment, the engineered antibody may be composed of one or more CDRs that are, for example, 90%, 95%, 98% or 99.5% identical to the H-CDRs listed in SEQ ID NOs: 49-103 or of L-CDR3 as given by SEQ ID NO: 155-199. 
     In addition to simply binding ATX, engineered antibodies, such as those described herein, may be selected for their retention of other functional properties of antibodies of the invention, such as the ability to inhibit ATX protein activity or and prevent formation of catalytic end products thereof, such as LPA, to LPAR positive cells, which binding would result in activation or proliferation of the LPAR positive cells in vivo. 
     Human monoclonal antibodies of the invention can be tested for binding to ATX by, for example, standard ELISA. Alternatively, human ATX-binding Mabs of the invention can be selected for the inability to bind ATX when one of Mab B6, B8, B13, B14 and B18 providing a neutralizing Mab. Human ATX-binding Mabs that do not neutralize ATX enzymatic activity can be selected by the capacity to bind to ATX when one of Mab B6, B8, B13, B14 and B18 is bound to ATX or by the inability to bind ATX when one of Mab B10, B15, or B16 is bound to ATX. 
     2. Generation of ATX-Neutralizing Antibodies 
     An ATX-neutralizing antibody exhibiting the desired bioactivity spectrum as exemplified herein by Mabs B1-B18 comprising the heavy chain and light chain sequences can be generated by a variety of techniques. 
     In another embodiment, the epitope bound by the antibodies of the invention, comprising as few as five to all of residues 201-214 and 244-255 which are believed to be the substrate binding and catalytic residues of ATX beta or all of the mature polypeptide residues 36-863 (SEQ ID NO: 11) or a nucleic acid coding sequence therefore, can be used to immunize a subject in order to produce the antibodies of the invention directly. Such polypeptide or DNA vaccines can also be administered for the purpose of treating, preventing, or ameliorating disease or symptoms of disease associated with the ATX activity. 
     In one embodiment and as exemplified herein, the human antibody is selected from a phage library, where that phage comprises human immunoglobulin genes and the library expresses human antibody binding domains as, for example, single chain antibodies (scFv), as Fabs, or some other construct exhibiting paired or unpaired antibody variable regions (Vaughan et lo al. Nature Biotechnology 14:309-314 (1996): Sheets et al. PITAS (USA) 95:6157-6162 (1998)); Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al. J. Mol. Biol., 222:581 (1991)). Human monoclonal antibodies of the invention can also be prepared using phage display methods for screening libraries of human immunoglobulin genes. Such phage display methods for isolating human antibodies are established in the art. See for example: U.S. Pat. Nos. 5,223,409; 5,403,484; and 5,571,698 to Ladner et al.; U.S. Pat. Nos. 5,427,908 and 5,580,717 to Dower et al.; U.S. Pat. Nos. 5,969,108 and 6,172,197 to McCafferty et al.; and U.S. Pat. Nos. 5,885,793; 6,521,404; 6,544,731; 6,555,313; 6,582,915 and 6,593,081 to Griffiths et al. 
     Phage clones are selected by and identified through a multi-step procedure known as biopanning. Biopanning is carried out by incubating phage displaying protein ligand variants (a phage display library) with a target, removing unbound phage by a washing technique, and specifically eluting the bound phage. The eluted phage are optionally amplified before being taken through additional cycles of binding and optional amplification that enriches the pool of specific sequences in favor of those phage clones bearing antibody fragments that display the best binding to the target. After several rounds, individual phage clones are characterized, and the sequences of the peptides displayed by the clones are determined by sequencing the corresponding DNA of the phage virion. 
     Fab Phage-pIX Library 
     In a specific embodiment of the phage display technology, a synthetic Fab library displayed on the pIX phage coat protein, described in Shi et al. J Mol Biol 397:385-396, 2010; WO29085462A1 and U.S. Ser. No. 12/546,850 and to be further detailed herein, is used to select binder from a repertoire of human IgG sequences derived from human germline genes. Libraries were constructed on four VL and three VH domains encoded by known IGV and IGJ germline sequences selected based on the frequency which the sequences have been observed to be present in human antibodies isolated from natural sources. The VH, IMGT nomenclature, selected are IGHV1-69 (SEQ ID NO: 1), IGHV3-23 (SEQ ID NO: 2), or IGHV5-51 (SEQ ID NO: 3). The diversity in the VH design produces heavy chains with variable length sequence in the CDR3 region with limited diversity positions in the H-CDR1 and H-CDR2 which remain at a constant length. Framework four (H-FR4) is held constant among all members of the library (FGQGTKVEIK, SEQ ID NO: 4). 
                            VH169, IGHV1-69*01 Length = 98, CDR1 = 31-35,           CDR2 = 50-66           (SEQ ID NO: 1)           QVQLVQSGAE VKKPGSSVKV SCKASGGTFS  SYX   1   IS WVRQA                       PGQGLEWMG X   2   IX   3   X   4   X   5   X   6   GTANY AQKFQG RVTI TADESTSTAY                       MELSSLRSED TAVYYCAR            
Where, in the 169 library X 1  is A or G, X 2  is G or W, X 3  may be I or S, X 4  may be P or A, X 5  may be I or Y and X 6  may be F or N.
 
                            VH323, IGHV3-23*01 Length = 98, CDR1 = 31-35,           CDR2 = 50-66           (SEQ ID NO: 2)           EVQLLESGGG LVQPGGSLRL SCAASGFTFS  X   1   YX   2   MX   3 WVRQA                       PGKGLEWVS X 4     IX   5   X   6   X   7   GX   8   STYY ADSVKG RFTI SRDNSKNTLY                       LQMNSLRAED TAVYYCAK            
Where, in the 323 library, X 1  may be S, D, N, or T; X 2  may be A, G, or W; X 3  may be S or H; X 4  may by V, A, N or G; X 5  may be S, N, K or W; X 6  may be Y, S, G, or Q; X 7  may be S or D; and X 8  may be S or G.
 
                            VH551, IGHV5-51*03 Length = 98, CDR1 = 31-35,           CDR2 = 50-66           (SEQ ID NO: 3)           EVQLVQSGAE VKKPGESLKI SCKGSGYSFT  X   1   YWIX   2 WVRQM                       PGKGLEWMG X   3   IX   4   PX   5   DSX   6   TRY SPSFQG QVTI SADKSISTAY                       LQWSSLKASD TAMYYCAR            
Where in the 551 library, X 1  may be S, N, or T; X 2  may be S or G; X 3  may be I or R; X 4  may by D or Y; X 5  may be G or S; X 6  may be D or Y.
 
     A FR4 or JH region having (11 residues), WGQGTLVTVSS (SEQ ID NO: 4), has been joined to the above sequences to form a complete heavy chain variable region. 
     The H-CDR1 and H-CDR2 positions that were targeted for diversification were determined by 1) diversity in germline genes; and 2) frequency found in contact with antigen in antibody-antigen complexes of known structure (Almagro J Mol Recognit. 17:132-143, 2004). The amino acid diversity at the selected positions was determined by 1) usage in germline; 2) amino acids that are most frequently observed in human rearranged V genes; 3) amino acids predicted to be result from single base somatic mutations; and 4) biochemical and biophysical properties of amino acids that contribute to antigen recognition. 
     The library incorporates diversity in the CDR3 of the VH (H3) mimicking the repertoire of human antibodies (Shi et al. 2010 supra) as shown below (FORMULA I) where the final length is between 7 and 14 residues. Among the CDR3 of over 5000 human variable regions, amino acids glycine (G) and alanine (A) are frequently used in all positions. In addition, aspartic acid (D) is frequently used in position 95 and tyrosine (Y) is frequently encoded in the positions preceding the canonical region of the J segment Amino acids phenylalanine (F), aspartic acid (D) and tyrosine (Y) predominate at positions 99-101 used in IgGs at these positions. Since these positions often serve as structural support to H-CDR3 and are less accessible to antigen and/or to surface of IgG, amino acids phenylalanine plus leucine (50/50 ratio) at position 99, aspartic acid at position 100 and tyrosine at position 101 were fixed. Thus, the sequence of Formula I is inserted between SEQ ID NOS: 1, 2, or 3 and SEQ ID NO: 4 to create a complete VH. 
       -(D)-(N) n (N+O) m (F)DY—  (I)
 
     Where: 
     (D)=Asp (D) and Gly (G) rich position.
 
(N)n=Ala (A) and Gly (G) rich position, n=3-7.
 
(O)m=Ala (A), Gly (G) and Y (Tyr) rich in, m=1-4.
 
(F)=The Phe (F) dominant position.
 
     Various versions of the library encompass pairings with fixed or diversified light chains derived also from the human germline repertoire. In the present invention, the four light-chain library VL kappa  genes (Kawasaki et al. 2001. Eur J Immunol 31: 1017-1028 and after Schaeble &amp; Zachau, 1993 Biol Chem Hoppe Seyler 374: 1001-1022) are A27 (IGKV3-20*01), B3 (IGKV4-1*01), L6 (IGKV3-11*01), and O12 (IGKV1-39*01) where the gene name in parentheses are the presumed corresponding IMGT gene. The Fabs are displayed on pIX via expression of a dicistronic vector wherein the VH-CH1 domain is fused to the coat protein sequence and the VL-CLkappa or VL-CLlambda is expressed as a free polypeptide which self-associates with the VH-CH1. The CDR regions are underlined. 
     Light Chain Variable Library Based on Vkappa (Vk) Germline Genes 
       
     
       
         
           
               
            
               
                 O12; IGKV1-39*01, IGKV1D-39*01 Length = 88; 
               
               
                 CDR1 = 24-34, CDR2 = 50-56 
               
               
                 (SEQ ID NO: 5) 
               
               
                 DIQMTQSPSS LSASVGDRVT ITC RASQSI X   1   X   2   X 3 LN WYQQKP 
               
               
                   
               
               
                 GKAPKLLIY X   4   ASSLQS GVPS RFSGSGSGTD FTLTISSLQP 
               
               
                   
               
               
                 EDFATYYC 
               
               
                   
               
               
                 L6, IGKV3-11*01 Length = 88, CDR1 = 24-34, 
               
               
                 CDR2 = 50-56 
               
               
                 (SEQ ID NO: 6) 
               
               
                 EIVLTQSPAT LSLSPGERAT LSC RASQSV X   1   X   2   X   3   LA WYQQKP 
               
               
                   
               
               
                 GQAPRLLIY X   4   ASNRAT GIPA RFSGSGSGTD FTLTISSLEP 
               
               
                   
               
               
                 EDFAVYYC 
               
               
                   
               
               
                 A27, IGKV3-20*01, Length = 89, CDR1 = 24-35, 
               
               
                 CDR2 = 51-57 
               
               
                 (SEQ ID NO: 7) 
               
               
                 EIVLTQSPGT LSLSPGERAT LSC RASQSVX   1   X   2   X   3   X   4   LA WYQQK 
               
               
                   
               
               
                 PGQAPRLLIY  X 5 ASSRAT GIP DRFSGSGSGT DFTLTISRLE 
               
               
                   
               
               
                 PEDFAVYYC 
               
               
                   
               
               
                 B3, DPK24, VKIVKlobeck; IGKV4-1*01 Length = 94, 
               
               
                 CDR1 = 24-40, CDR2 = 56-62 
               
               
                 (SEQ ID NO: 8) 
               
               
                 DIVMTQSPDS LAVSLGERAT INC KSSQSVL   X   1   SSNNX 2 NX   3   LA   
               
               
                   
               
               
                 WYQQKPGQPP KLLIY X   4   ASTR   ES GVPDRFSG SGSGTDFTLT 
               
               
                   
               
               
                 ISSLQAEDVA VYYC 
               
            
           
         
       
     
     The diversity at the specified positions for each variable region scaffold are summarized in Table 1 below where the amino acids single-letter code is used and is present in the alternative at the specified positions as shown in  FIG. 1 . 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 1 
               
               
                   
               
               
                   
                 Kabat 
                 O12 
                 L6 
                 A27 
                 B3 
               
               
                 CDR 
                 Position 
                 SEQ ID NO: 5 
                 SEQ ID NO: 6 
                 SEQ ID NO: 7 
                 SEQ ID NO: 8 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 1 
                 30 
                 X 1   
                 SRNAD 
                 X 1   
                 SRNAD 
                 X 1   
                 SRNTD 
                   
                 L 
               
               
                   
                 30a 
                   
                 — 
                   
                 — 
                 X 2   
                 SNR 
                 X 1   
                 YSHFA 
               
               
                   
                 30e 
                   
                 — 
                   
                 — 
                   
                 — 
                   
                   
               
               
                   
                 30f 
                   
                   
                   
                   
                   
                   
                 X 2   
                 KTNE 
               
               
                   
                 31 
                 X 2   
                 SNKDG 
                 X 2   
                 NSKD 
                 X 3   
                 SNRADH 
                   
                 N 
               
               
                   
                 32 
                 X 3   
                 YHNDW 
                 X 3   
                 YWDF 
                 X 4   
                 YFHQSEK 
                 X 3   
                 YFHNW 
               
               
                   
                   
                   
                 FSAV 
                   
                 HSAN 
                   
                   
                   
                 DAS 
               
               
                   
               
               
                 2 
                 50 
                 X 4   
                 FYTNKA 
                 X 4   
                 ADKGY 
                 X 5   
                 ADGS 
                 X 4   
                 WSRDY 
               
               
                   
                   
                   
                 DG 
                   
                 FTN 
                   
                   
                   
                 A 
               
               
                   
               
            
           
         
       
     
     The VL CDR3 in all of the libraries has seven residues wherein the first two residues are glutamine (Gln, Q) and the residue corresponding to Kabat residue 95 is proline (Pro, P). For L-CDR3 the sequence corresponds to QQX 1 X 2 X 3 X 4 PX 5 T (SEQ ID NO: 9), where variegation are as in the table below and at the residue positions are according to Kabat. 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 2 
               
               
                   
               
               
                   
                 Kabat 
                   
                   
                   
                   
               
               
                 Res- 
                 CDR3 
                   
                   
                   
                   
               
               
                 idue 
                 Position 
                 O12 
                 L6 
                 A27 
                 B3 
               
               
                   
               
             
            
               
                 X1 
                 91 
                 SAYHPD 
                 RYSGF 
                 YSHA 
                 YSHA 
               
               
                   
               
               
                 X2 
                 92 
                 FIYHNDKGRE 
                 RHNSL 
                 YNDSHIFKG 
                 YNDSHIFKG 
               
               
                   
               
               
                 X3 
                 93 
                 STHNDRG 
                 NDKR 
                 SNTDGHR 
                 SNTDGHR 
               
               
                   
               
               
                 X4 
                 94 
                 TYLVFSRGPI 
                 WA 
                 TYLVFAS 
                 TYLVFAS 
               
               
                   
               
               
                 X5 
                 96 
                 LWRFYIN 
                 WYFLIR 
                 WYFLIR 
                 WYFLIR 
               
               
                   
               
            
           
         
       
     
     As the variable sequence varies in length from gene to gene, diversity in a particular residue location within a hypervariable loop or CDR can be described as follows using the residue numbering as defined in Al-Lazikani B, Lesk A M, Chothia C, 1997 (Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 273: 927-948). In this system, the changes in length of the hypervariable loops are accommodated by the designation of subpositions a, b, c, etc. for a given residue. 
     A framework 4 (FR4) segment such as JK4, FGQGTKVEIK (SEQ ID NO: 10) was used to form a complete human light chain variable region. 
     Fab affinity for diverse protein targets from 0.2 to 20 nM has been demonstrated in initial selections. 
     Methods for an integrated maturation process for improving binding parameters consisting of reshuffling VL or VH diversity or, alternatively, directed or limited VL modification are accomplished using the vectors and primers designed and used for the libraries as described in the referenced publication, as taught herein, and combined with what it known in the art. 
     Alternative Sources of ATX-Binding Immunoglobulin Domains 
     ATX binding antibodies with the characteristics of the human Mabs disclosed herein may be made or binding fragments sourced from immunoglobulin domains formed by a number of methods, including the standard somatic cell hybridization technique (hybridoma method) of Kohler and Milstein (1975) Nature 256:495. In the hybridoma method, a mouse or other appropriate host animal, such as a hamster or macaque monkey, is immunized as described herein to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)). 
     An ATX-neutralizing antibody can also be optionally generated by immunization of a transgenic animal (e.g., mouse, rat, hamster, non-human primate, and the like) capable of producing a repertoire of human antibodies, as described herein and/or as known in the art. Cells that produce a human anti-ATX antibody can be isolated from such animals and immortalized using suitable methods, such as the methods described herein. Alternatively, the antibody coding sequences may be cloned, introduced into a suitable vector, and used to transfect a host cell for expression and isolation of the antibody by methods taught herein and those known in the art. 
     The use of transgenic mice carrying human immunoglobulin (Ig) loci in their germline configuration provide for the isolation of high affinity fully human monoclonal antibodies directed against a variety of targets including human self antigens for which the normal human immune system is tolerant (Lonberg, N. et al., U.S. Pat. No. 5,569,825, U.S. Pat. No. 6,300,129 and 1994, Nature 368:856-9; Green, L. et al., 1994, Nature Genet. 7:13-21; Green, L. &amp; Jakobovits, 1998, Exp. Med. 188:483-95; Lonberg, N and Huszar, D., 1995, Int. Rev. Immunol. 13:65-93; Kucherlapati, et al. U.S. Pat. No. 6,713,610; Bruggemann, M. et al., 1991, Eur. J. Immunol. 21:1323-1326; Fishwild, D. et al., 1996, Nat. Biotechnol. 14:845-851; Mendez, M. et al., 1997, Nat. Genet. 15:146-156; Green, L., 1999, J. Immunol. Methods 231:11-23; Yang, X. et al., 1999, Cancer Res. 59:1236-1243; Brüggemann, M. and Taussig, M J., Curr. Opin. Biotechnol. 8:455-458, 1997; Tomizuka et al. WO02043478). The endogenous immunoglobulin loci in such mice can be disrupted or deleted to eliminate the capacity of the animal to produce antibodies encoded by endogenous genes. In addition, companies, such as Abgenix, Inc. (Freemont, Calif.) and Medarex (San Jose, Calif.) can be engaged to provide human antibodies directed against a selected antigen using technology as described above. 
     Preparation of polypeptides for use as target ligands in panning strategies and as immunogenic antigens can be performed using any suitable technique, such as recombinant protein production. The target ligand or fragment thereof in the form of purified protein, or protein mixtures including whole cells or cell or tissue extracts, or, in the case of an immunization, the antigen can be formed de novo in the animal&#39;s body from nucleic acids encoding said antigen or a portion thereof. 
     The isolated nucleic acids of the present invention can be made using (a) recombinant methods, (b) synthetic techniques, (c) purification techniques, or combinations thereof, as well-known in the art. DNA encoding the monoclonal antibodies is readily isolated and sequenced using methods known in the art (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of human antibody regions). Where a hybridoma is produced, such cells can serve as a source of such DNA. Alternatively, using display techniques wherein the coding sequence and the translation product are linked, such as phage or ribosomal display libraries, the selection of the binder and the nucleic acid is simplified. After phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria. 
     Human Antibodies 
     The invention specifically provides human immunoglobulins (or antibodies) which bind human ATX. These antibodies can also be characterized as engineered or adapted. The immunoglobulins have variable region(s) substantially from a human germline immunoglobulin and include directed variations in residues known to participate in antigen recognition, e.g. the CDRs of Kabat or the hypervariable loops as structurally defined. The constant region(s), if present, are also substantially from a human immunoglobulin. The human antibodies exhibit K D  for ATX of at least about 10 −6  M (1 μM), about 10 −7  M (100 nM), 10 −8  (10 nM), 10 −9  M (1 nM), or less than 100 pM (10 −10 ). To affect a change in affinity, e.g., improve affinity or reduce K D , of the human antibody for ATX, substitutions in either the CDR residues or other residues may be made. 
     The source for production of human antibody which binds to ATX is preferably the sequences provide herein as the variable regions, frameworks and/or CDRs, noted as SEQ ID NO: 16-201 identified as capable of binding human ATX and cross-reacting with ATX homologs of other species, e.g. mouse, using a repertoire of human derived Fab displayed on filamentous phage particles. 
     The substitution of any of the CDRs into any human variable domain framework is most likely to result in retention of their correct spatial orientation if the human variable domain framework adopts the same or similar conformation to the parent variable framework from which the CDRs originated. The heavy and light chain variable framework regions to be paired in the final Mab can be derived from the same or different human antibody sequences. The human antibody sequences can be the sequences of naturally occurring human antibodies, be derived from human germline immunoglobulin sequences, or can be consensus sequences of several human antibody and/or germline sequences. 
     Suitable human antibody sequences are identified by computer comparisons of the amino acid sequences of the mouse variable regions with the sequences of known human antibodies. The comparison is performed separately for heavy and light chains but the principles are similar for each. 
     With regard to the empirical method, it has been found to be particularly convenient to create a library of variant sequences that can be screened for the desired activity, binding affinity or specificity. One format for creation of such a library of variants is a phage display vector. 
     Another method of determining whether further substitutions are required, and the selection of amino acid residues for substitution, can be accomplished using computer modeling. Computer hardware and software for producing three-dimensional images of immunoglobulin molecules are widely available. In general, molecular models are produced starting from solved structures for immunoglobulin chains or domains thereof. The chains to be modeled are compared for amino acid sequence similarity with chains or domains of solved three dimensional structures, and the chains or domains showing the greatest sequence similarity is/are selected as starting points for construction of the molecular model. The solved starting structures are modified to allow for differences between the actual amino acids in the immunoglobulin chains or domains being modeled, and those in the starting structure. The modified structures are then assembled into a composite immunoglobulin. Finally, the model is refined by energy minimization and by verifying that all atoms are within appropriate distances from one another and that bond lengths and angles are within chemically acceptable limits. 
     Because of the degeneracy of the code, a variety of nucleic acid sequences will encode each immunoglobulin amino acid sequence. The desired nucleic acid sequences can be produced by de nova solid-phase DNA synthesis or by PCR mutagenesis of an earlier prepared variant of the desired polynucleotide. All nucleic acids encoding the antibodies described in this application are expressly included in the invention. 
     The variable segments of human antibodies produced as described herein are typically linked to at least a portion of a human immunoglobulin constant region. The antibody will contain both light chain and heavy chain constant regions. The heavy chain constant region usually includes CH1, hinge, CH2, CH3, and, sometimes, CH4 domains. 
     The human antibodies may comprise any type of constant domains from any class of antibody, including IgM, IgG, IgD, IgA and IgE, and any subclass (isotype), including IgG1, IgG2, IgG3 and IgG4. When it is desired that the humanized antibody exhibit cytotoxic activity, the constant domain is usually a complement-fixing constant domain and the class is typically IgG 1 . When such cytotoxic activity is not desirable, the constant domain may be of the IgG 2  class. The humanized antibody may comprise sequences from more than one class or isotype. 
     Nucleic acids encoding human or humanized light and heavy chain variable regions, optionally linked to constant regions, are inserted into expression vectors. The light and heavy chains can be cloned in the same or different expression vectors. The DNA segments encoding immunoglobulin chains are operably linked to control sequences in the expression vector(s) that ensure the expression of immunoglobulin polypeptides. Such control sequences include a signal sequence, a promoter, an enhancer, and a transcription termination sequence (see Queen et al., Proc. Natl. Acad. Sci. USA 86, 10029 (1989); WO 90/07861; Co et al., J. Immunol. 148, 1149 (1992), which are incorporated herein by reference in their entirety for all purposes). 
     3. Methods of Using an Anti-ATX Antibody 
     As described in detail below, the present invention demonstrates that isolated monoclonal antibodies having the variable domains of the 57 Fabs listed in Table 3 bind different or overlapping epitopes on ATX and display in vitro and/or in vivo ATX inhibiting activities. Significantly, the reactivity of the selected MAbs includes the ability to dose-dependently block ATX lysophospholipase activity thereby reducing LPA generation in the region surrounding ATX. Thus, the Mabs of the invention can be used to prevent or reduce the effects of LPA binding to local LPA receptors, LPA receptor signal transduction and ameliorate effects caused by LPA-driven cell migration. 
     Given the properties of the monoclonal antibodies as described in the present invention, the antibodies or antigen binding fragments thereof are suitable both as detecting (diagnostic or prognostic), therapeutic and prophylactic agents for treating or preventing ATX-associated conditions in humans and animals. 
     In general, use will comprise administering a therapeutically or prophylactically effective amount of one or more monoclonal antibodies or antigen binding fragments of the present invention, or an antibody or molecule selected to have similar spectra of binding and biologic activity, to a susceptible subject or one exhibiting a condition in which ATX activity is known to have pathological sequelae, such as inflammatory or autoimmune disorders or tumor growth and metastasis. Any active form of the antibody can be administered, including Fab and F(ab′)2 fragments. 
     Preferably, the antibodies used are compatible with the recipient species such that the immune response to the MAbs does not result in an unacceptably short circulating half-life or induce an immune response to the MAbs in the subject. The MAbs administered may exhibit some secondary functions, such as binding to Fc receptors of the subject and activation of ADCC mechanisms, in order to deplete the ATX-associated cell population using cytolytic or cytotoxic mechanisms or they may be engineered to by limited or devoid of these secondary effector functions in order to preserve any ATX-associated cell population. 
     Treatment of individuals may comprise the administration of a therapeutically effective amount of the antibodies of the present invention. The antibodies can be provided in a kit as described below. The antibodies can be used or administered as a mixture, for example, in equal amounts, or individually, provided in sequence, or administered all at once. In providing a patient with antibodies, or fragments thereof, capable of binding to ATX, or an antibody capable of protecting against ATX in a recipient patient, the dosage of administered agent will vary depending upon such factors as the patient&#39;s age, weight, height, sex, general medical condition, previous medical history, etc. 
     In a similar approach, another therapeutic use of the monoclonal antibodies of the present invention is the active immunization of a patient using an anti-idiotypic antibody raised against one of the present monoclonal antibodies Immunization with an anti-idiotype which mimics the structure of the epitope could elicit an active anti-ATX response (Linthicum, D. S. and Farid, N. R., Anti-idiotypes, Receptors, and Molecular Mimicry (1988), pp 1-5 and 285-300). 
     The antibodies capable of protecting against unwanted ATX bioactivity are intended to be provided to recipient subjects in an amount sufficient to effect a reduction, resolution, or amelioration in the ATX-related symptom or pathology. An amount is said to be sufficient or a “therapeutically effective amount” to “effect” the reduction of symptoms if the dosage, route of administration, etc. of the agent are sufficient to influence such a response. Responses to antibody administration can be measured by analysis of subject&#39;s affected tissues, organs, or cells as by imaging techniques or by ex vivo analysis of tissue samples. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient. 
     Therapeutic Applications 
     The ATX-neutralizing antibodies of the present invention, antigen binding fragments, or specified variants thereof can be used to measure or cause effects in an cell, tissue, organ or animal (including mammals and humans), to diagnose, monitor, modulate, treat, alleviate, help prevent the incidence of, or reduce the symptoms of, a condition mediated, affected or modulated by ATX or cells expressing ATX. Thus, the present invention provides a method for detecting the presence or concentration of ATX, or modulating or treating at least one ATX related disease, in a cell, tissue, organ, animal, or patient, as known in the art or as described herein, using at least one ATX antibody of the present invention. 
     ATX is known to be up-regulated in a variety of disease states that involve the release of inflammatory mediators and has been implicated in diverse biological roles including metastatic spread of cancerous cells, proliferation of tumor cells, fibrosis, pain, acute lung injury, sepsis, and inflammation. Particular indications are discussed below. Experimental evidence (WO2011/151461A2) indicated that the level of ATX that is produced by synovial fibroblasts in RA individuals is regulated by tumor necrosis factor alpha (TNF). Addition of TNF to synovial fibroblast derived from healthy individuals led to increased expression of ATX. Moreover, inhibition of TNF in cultures of synovial fibroblasts harvested from an affected joint in an RA patient led to a reduced level of ATX being produced. 
     Indications 
     The biological outcome of ATX action depends on the local availability of its substrates, the presence of regulatory cofactors and the spectrum of LPA receptors expressed on nearby target cells. The major physiological substrate for ATX is LPC. LPC is abundantly present in plasma and serum (at &gt;100 μM) in a predominantly albumin-bound form (The K m  of ATX for LPC is approx. 100 which is in the range of LPC plasma concentrations. Blocking ATX enzymatic activity or removal of ATX protein by Mab which specifically bind ATX with a K D  of less than 1 μM can be a prophylactic or therapeutic strategy for the treatment of a variety diseases in which ATX production is enhanced and/or deleterious cell responses are produced by binding of the enzymatic products of ATX on lysophospholipids including, but not limited to LPC and sphingosylphosphorylcholine, the downstream effects of the interaction of those products, such as LPA and S1P to cell receptors. Thus, ATX regulates cell activation by changing signaling induced by LPC versus LPA. LPC and ATX may increase locally during inflammation. 
     LPA 1  (Edg-2), a receptor for LPA is found ubiquitously inhuman tissues: brain, heart, placenta, colon, small intestine, prostate, testis, ovary, pancreas, spleen, kidney, skeletal muscle, and thymus. The nervous system is a major site for lpa 1  expression and which is restricted during embryonic development to the neocortical neurogenic region called ventricular zone, which disappears at the end of cortical neurogenesis, just before birth. Postnatal lpa 1  expression is apparent in and around developing white matter tracts and during the process of myelination by oligodendrocytes as well as in Schwann cells, the myelinating cells of the peripheral nervous system. These observations identify important functions for receptor-mediated LPA signaling in neurogenesis, cell survival, and myelination. Expression of lpa 2  (edg-4) is observed in the testis, kidney, lung, thymus, spleen, and stomach of adult mice and in the human testis, pancreas, prostate, thymus, spleen, and peripheral blood leukocytes. Expression of lpa 2  is upregulated in various cancer cell lines. The LPA 2  receptor may have overlapping specificity and distribution with LPA 1  providing redundancy in the signaling pathways with include MAPK activation, PLC activation, Ca 2+  mobilization, PI3K/Akt activation and stress fiber formation. The LPA 3  receptor (Edg-7) is distinct from LPA 1  and LPA 2  in its ability to couple G-proteins and is much less responsive to LPA species with saturated acyl chains. Nonetheless, LPA 3  can mediate pleiotropic LPA-induced signaling that includes PLC activation, Ca 2+  mobilization, AC inhibition/activation, and MAPK activation. LPA 3 . Overexpression of LPA 3  in neuroblastoma cells leads, surprisingly, to neurite elongation, whereas that of LPA 1  or LPA 2  results in neurite retraction and cell rounding when stimulated with LPA. Expression of lpa 3  is observed in adult mouse testis, kidney, lung, small intestine, heart, thymus, and brain. In humans, it is found in the heart, pancreas, prostate, testis, lung, ovary, and brain (frontal cortex, hippocampus, and amygdala). LPA 4  (p2y 9 /GPR23) is of divergent sequence compared to LPA 1 -LPA 3  and more similar to the receptor for another lipid mediator, platelet aggregation factor (PAF). LPA 4  mediates LPA-induced Ca 2+  mobilization and cAMP accumulation. The lpa 4  gene is expressed at very high levels in the ovary and, to a much lesser extent, in the pancreas, thymus, and human kidney and skeletal muscle (See Ishii et al. 2004 Annual Rev Biochemistry 73: 321-354, for a review). 
     According to the present invention there is therefore provided the use of an antibody or antibody fragment, which competes for binding to catalytically active ATX with an antibody as described herein. In one aspect, the present invention provides the use of an antibody or antibody fragment selected from the group B1-B18 and related or re-engineered antibodies or fragments thereof in the manufacture of a medicament for the treatment or prophylaxis types and stages of inflammation driven pathology, proliferative and metastatic disease such as cancer, and neurological disorders. 
     In particular, highly metastatic cancers or cancer progression mechanism which involve angiogenesis wherein one or more cell types secrete ATX or express one or more LPA receptors can be treated with ATX-binding Mabs of the invention. Specific examples of cancers that can be treated by the methods encompassed by the invention include, but are not limited to, Hodgkin lymphoma, follicular lymphoma, glioblastoma, non-small-cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, breast cancer, ovarian cancer, and thyroid carcinomas. 
     Cancers that can be treated by the methods encompassed by the invention include, but are not limited to, neoplasms, tumors, metastases, or any disease or disorder characterized by uncontrolled cell growth. The cancer may be a primary or metastatic cancer. In a preferred embodiment, the cancer that is being managed, treated or ameliorated in accordance with the methods of the invention is a cancer secreting ATX or one comprised of cells expressing a LPA receptor or where LPA receptor is present on cells in the tumor microenvironment. Additional cancers include, but are not limited to, the following: leukemias such as but not limited to, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia leukemias and myelodysplastic syndrome, chronic leukemias such as but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia Vera; lymphomas such as but not limited to Hodgkin&#39;s disease, non-Hodgkin&#39;s disease; multiple myelomas such as but not limited to smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullaryplasmacytoma; Waldenstrom&#39;s macroglobulinemia; bone cancer and connective tissue sarcomas such as but not limited to bone sarcoma, myeloma bone disease, osteosarcoma, chondrosarcoma, Ewing&#39;s sarcoma, Paget&#39;s disease of bone, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi&#39;s sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, neurilemmoma, rhabdomyosarcoma, synovial sarcoma; brain tumors such as but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary brain lymphoma; breast cancer including but not limited to adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget&#39;s disease (including juvenile Paget&#39;s disease), and inflammatory breast cancer; adrenal cancer such as but not limited to pheochromocytom and adrenocortical carcinoma; thyroid cancer such as but not limited to papillary or follicular thyroid cancer, medullary thyroid cancer and anaplastic thyroid cancer; pancreatic cancer such as but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; pituitary cancers such as but limited to Cushing&#39;s disease, prolactin-secreting tumor, acromegaly, and diabetes insipidus; eye cancers such as but not limited to ocular melanoma such as iris melanoma, choroidal melanoma, and cilliary body melanoma, and retinoblastoma; vaginal cancers such as squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer such as squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget&#39;s disease; cervical cancers such as but not limited to, squamous cell carcinoma, and adenocarcinoma; uterine cancers such as but not limited to endometrial carcinoma and uterine sarcoma; ovarian cancers such as but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; esophageal cancers such as but not limited to, squamous cancer, adenocarcinoma, adenoid cyctic carcinoma, mucoopidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; stomach cancers such as but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; colon cancers; rectal cancers; liver cancers such as but not limited to hepatocellular carcinoma and hepatoblastoma, gallbladder cancers such as adenocarcinoma; cholangiocarcinomas such as but not limited to papillary, nodular, and diffuse; lung cancers such as non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma and small-cell lung cancer; testicular cancers such as but not limited to germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, choriocarcinoma (yolk-sac tumor), prostate cancers such as but not limited to, adenocarcinoma, lelomyosarcoma, and rhabdomyosarcoma; penal cancers; oral cancers such as but not limited to squamous cell carcinoma; basal cancers; salivary gland cancers such as but not limited to adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; pharynx cancers such as but not limited to squamous cell cancer, and verrucous; skin cancers such as but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, acral lentiginous melanoma; kidney cancers such as but not limited to renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, transitional cell cancer (renal pelvis and/or uterer); Wilms&#39; tumor; bladder cancers such as but not limited to transitional cell carcinoma, squamous cell cancer, adenocarcinoma, carcinosarcoma. In addition, cancers include myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangioendotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma and papillary adenocarcinomas (see Vincent T. DeVita, Samuel Hellman, Steven A. Rosenberg. “ Cancer: Principles and Practice of Oncology ”, (Philadelphia, Pa.: J Lippincott Williams &amp; Wilkins, 2005 7th Ed.). Pre-malignant conditions may also be treated by the methods and compositions of the invention. 
     Recent reports have shown that ATX is elevated in intra-articular matrix from tissue explants. ATX may be upregulated in adipocytes and adipose tissue ATX is up-regulated in patients exhibiting both insulin resistance and impaired glucose tolerance. These effects may be driven by other inflammatory cytokines such as TNFalpha, IL8, or IL6. Autotaxin released from adipocytes, catalyzes LPA synthesis, and activates preadipocyte proliferation, adipocyte differentiation and obesity. Inhibition of ATX may help control insulin resistance in Type 2 diabetes and obesity. Reduction of LPA may reduce the amount of LPA in oxidized LDL and atherosclerotic plaques thus preventing arterial damage or neointimal proliferation and blockages. Various indications related to effects on cells having one of more LPA receptor type include vascular disease due to inflammatory arthropathy, rheumatoid arthritis, diabetes and related pathologies, obesity, the effects of oxidative damage, the effects of reperfusion after an ischemic event, gastrointestinal tissue inflammation or necrosis, cardiovascular disorders, rejection of tissue transplantation, wound healing, and Alzheimer&#39;s disease. 
     According to the present invention there is therefore provided the use of an antibody or antibody fragment, which competes for binding to catalytically active ATX with and antibody described herein selected from the group B1-B18, in the manufacture of a medicament for the treatment or prophylaxis of a pro-inflammatory process in which ATX directly or indirectly, such as through the release of inflammatory cytokines, leads to pathogenesis in tissues or organs especially in the skin, lungs, and joints. Such pathologies include inflammation related to osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, neuropathic arthropathy, rheumatic fever, Reiter&#39;s syndrome, progressive systemic sclerosis, primary biliary cirrhosis, pemphigus, pemphigoid, necrotizing vasculitis, myasthenia gravis, multiple sclerosis, lupus erythematosus, polymyositis, sarcoidosis, granulomatosis, vasculitis, pernicious anemia, CNS inflammatory disorder, autoimmune haemolytic anemia, Hashimoto&#39;s thyroiditis, Graves disease, Reynard&#39;s syndrome, glomerulonephritis, dermatomyositis, chronic active hepatitis, celiac disease, autoimmune complications of AIDS, atrophic gastritis, and Addison&#39;s disease, endotoxemia or septic shock (sepsis), or one or more of the symptoms of sepsis and other types of acute and chronic inflammation. Those patients who are more particularly able to benefit from the method of the invention are those suffering from infection by  E. coli, Haemophilus  influenza B,  Neisseria meningitides , staphylococci, or pneumococci. 
     Other conditions that are associated with ATX and amenable to treatment or preventative therapy with the antibodies of the invention include fibrotic disease such as pulmonary fibrosis, diabetic nephropathy, idiopathic pulmonary fibrosis, systemic sclerosis, and cirrhosis. 
     Administration and Dosing 
     The invention provides for stable formulations of an ATX-neutralizing antibody, which is preferably an aqueous phosphate buffered saline or mixed salt solution, as well as preserved solutions and formulations as well as multi-use preserved formulations suitable for pharmaceutical or veterinary use, comprising at least one ATX-neutralizing antibody in a pharmaceutically acceptable formulation. Suitable vehicles and their formulation, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in e.g. Remington: The Science and Practice of Pharmacy, 21st Edition, Troy, D. B. ed., Lipincott Williams and Wilkins, Philadelphia, Pa. 2006, Part 5, Pharmaceutical Manufacturing pp 691-1092, See especially pp. 958-989. 
     The ATX-binding and/or an ATX-neutralizing antibody in either the stable or preserved formulations or solutions described herein, can be administered to a patient in accordance with the present invention via a variety of delivery methods including intravenous (I.V.); intramuscular (I.M.); subcutaneously (S.C.); transdermal; pulmonary; transmucosal; using a formulation in an implant, pump, cartridge, micropump; or other means appreciated by the skilled artisan, as well-known in the art. 
     For example, site specific administration may be to body compartment or cavity such as intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, vaginal, rectal, buccal, sublingual, intranasal, or transdermal means. 
     In general, if administering a systemic dose of the antibody, it is desirable to provide the recipient with a dosage of antibody which is in the range of from about 1 ng/kg-100 ng/kg, 100 ng/kg-500 ng/kg, 500 ng/kg-1 μg/kg, 1 μg/kg-100 μg/kg, 100 μg/kg-500 μg/kg, 500 μg/kg-1 mg/kg, 1 mg/kg-50 mg/kg, 50 mg/kg-100 mg/kg, 100 mg/kg-500 mg/kg (body weight of recipient), although a lower or higher dosage may be administered. Of course, suitable dosages of an antagonist of the present invention will vary, depending upon factors such as the disease or disorder to be treated, the route of administration and the age and weight of the individual to be treated and the nature of the antagonist. Without being bound by any particular dosages, it is believed that for instance for parenteral administration, a daily dosage of from 0.01 to 20 mg/kg of an antibody (or other large molecule) of the present invention (usually present as part of a pharmaceutical composition as indicated above) may be suitable for treating a typical adult. 
     The treatment may be given in a single dose schedule, or preferably a multiple dose schedule in which a primary course of treatment may be with 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reinforce the response, for example, at 1-4 months for a second dose, and if needed, a subsequent dose(s) after several months. Examples of suitable treatment schedules include: (i) 0, 1 month and 6 months, (ii) 0, 7 days and 1 month, (iii) 0 and 1 month, (iv) 0 and 6 months, or other schedules sufficient to elicit the desired responses expected to reduce disease symptoms, or reduce severity of disease. 
     The antibodies of the present invention may be used alone or in combination with other agents such as steroids (prednisone etc.), cyclophosphamide, cyclosporin A or a purine analogue (e.g. methotrexate, 6-mercaptopurine, or the like), or antibodies such as an anti-lymphocyte antigen antibody, an anti-leukocyte antigen antibody, a TNF antagonist e.g. an anti-TNF antibody or TNF inhibitor e.g. soluble TNF receptor, or agents such as NSAIDs or other cytokine inhibitors. 
     The present invention will now be described with reference to the following specific, non-limiting examples. 
     Example 1 
     Reagents and Assays 
     In order to select and characterize ATX-binding antibodies, constructs of human and mouse ATX were generated for mammalian cell expression. The three human ATX isoforms were produced using mammalian expression system with purification tag (GSHHHHHH, SEQ ID NO: 15) fused at the N-terminus of ATX at the propeptide cleavage site, which are: beta, the most abundant form in humans, SEQ ID NO: 11 residues 49-863; alpha, SEQ ID NO. 12 residues 49-915; and gamma, SEQ ID NO: 13 residues 49-888. Recombinant human ATX beta was used in most of the antibody characterization and was also biotinylated and used for phage panning. Both isoform beta and gamma were overexpressed easily and showed strong enzymatic activities. 
     In addition to human ATX beta isoform, recombinant mouse ATX beta isoform from R&amp;D systems (UnitProt Q9R1E6, SEQ ID NO: 14, Cat No. 6187-EN-010) was also used in characterizing the antibodies. 
     Assays Used 
     ATX Inhibition Assay, Using the Fluorescent Autotaxin Substrate FS-3 
     The substrate FS-3 (Echelon Biosciences, Cat. No. L2000, U.S. Pat. No. 7,459,285) is a lysophospholipid-derivative which displays an increase in fluorescence when hydrolyzed by ATX, therefore activity can be measured by monitoring the rate of increase in fluorescence. Recombinant human autotaxin was diluted to 10 nM in assay buffer (50 mM Tris pH 8.0, 140 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.1% fatty acid free BSA). The FS-3 substrate was diluted to 2 uM in assay buffer. Test mAbs were diluted to 10 μg/ml in assay buffer. 
     In a white 384 well plate, 15 ul autotaxin and 15 μl mAb were added in duplicate wells and incubated at room temperature for 10 minutes while shaking. Then 30 μl FS-3 substrate was added to each well. Final concentrations are 2.5 nM ATX, 2.5 μg/ml mAb, and 1 uM FS-3 in a volume of 60 μl. 
     Fluorescence (Excitation 485 nm, Emission 535 nm) was measured using a Molecular Devices Spectramax M2 plate reader in kinetic mode for 20 minutes with a 30 second interval, and the slope of the rate of change in fluorescence was calculated using Softmax Pro software. Controls included ATX in the absence of mAb, ATX with an isotype control mAb, and the FS-3 substrate in the absence of ATX. The rates are normalized to the rate of autotaxin hydrolysis of FS-3 with no inhibitor added to the reaction. 
     ATX Inhibition Assay of Autotaxin LPC Hydrolysis, by Detection of Choline with Amplex Red 
     ATX catalyzes the hydrolysis of LPC into LPA and choline. In this enzyme-coupled assay, ATX activity is monitored indirectly using 10-acetyl-3,7-dihydrophenoxazine (Amplex Red reagent), a sensitive fluorogenic probe for hydrogen peroxide. Choline is oxidized by choline oxidase to betaine and hydrogen peroxide, which reacts with Amplex Red reagent in the presence of horseradish peroxidase to generate a highly fluorescent product. ATX activity is measured by monitoring the rate of increase in fluorescence. The protocol was based on the manufacturer&#39;s instructions for the Amplex Red Phospholipase D Assay Kit (Invitrogen, Cat. No. A12219) with minor modifications. Autotaxin was diluted to 1.5 ug/ml in 1× Reaction Buffer. The supplied lecithin was substituted with lysophosphocholine (Sigma, L4129) at the same concentration. Each well contained 10 μL autotaxin (0.15 μg/ml or 1.5 nM) or buffer, 40 μl sample, and 50 μL Amplex Red working solution. 
     Affinity Analysis 
     Affinity measurements using surface plasmon resonance (SPR) were performed using a Biacore 3000 optical biosensor (Biacore) for ATXB3, ATXB6, ATXB8, ATXB9, ATXB13, and ATXB14. A biosensor surface was prepared by coupling anti-Penta-His antibody (Qiagen, Cat No. 34660) to the carboxymethylated dextran surface of a CM-5 chip (Biacore, Cat No. BR-1000-14) using the manufacturer instructions for amine-coupling chemistry. Approximately 15,000 RU (response units) of anti-Penta-His antibody were immobilized in each of four flow cells. The kinetic experiments were performed at 25° C. in running buffer (PBS+0.01% P20+100 ug/ml BSA). Serial dilutions of anti-ATX mAbs (ATXB3, B6, B8, B9, B13, B14) from 900 nM to 0.412 nM were prepared in running buffer. About 80 RU of human ATX beta-His tagged proteins were captured on flow cell 2 of the sensor chip. Flow cell 1 was used as reference surface. Capture of ATX was followed by five minutes injection (association phase) of anti-ATX mAbs at 50 uL/min, followed by 15 minutes of buffer flow (dissociation phase). The chip surface was regenerated by 15 seconds injection of 100 mM H 3 PO 4  (Sigma, Cat No. 7961) at 50 uL/min. The collected data were processed using BIAevaluation software, version 3.2 (Biacore). First, double reference subtraction of the data was performed by subtracting the curves generated by buffer injection from the reference-subtracted curves for analyte injections. Then kinetic analysis of the data was performed using the Bivalent Analyte binding model with global fitting. Kd1 (K on ) was calculated as intrinsic KD with minimum avidity. The result for each mAb was reported in the format of Ka1 (On-rate, K on ), Kd1 (Off-rate, K off ) and KD1 (Equilibrium dissociation constant). Affinity measurements for ATXB18 were performed on a Proteon XPR36 system (Bio-Rad), using a protocol similar to the one used on the Biacore platform. 
     Bio-Layer Interferometry 
     Biomolecular interaction analysis using bio-layer interferometry were performed using an Octet RED384 instrument (Forte Bio). ATX was diluted to 20 μg/ml and mAbs to 10 μg/ml in PBSTB (PBS, 0.02% Tween, 0.1% BSA). Hexa-histidine-tagged ATX was bound to anti-Penta-His biosensors (ForteBio, Cat No. 18-0020) for 4 minutes, followed by a two minute primary mAb binding period then a two minute secondary mAb binding period. Biosensor traces were then analyzed qualitatively to determine if simultaneous binding occurred for each mAb pair. 
     Example 2 
     Selection of 57 ATX Binding Fab Clones 
     The de novo Fab-pIX libraries have been described Shi et al. J Mol Biol 397:385-396, 2010; WO09085462A1; U.S. Ser. No. 12/546,850; and herein above are designated 169, 323 and 551 which references the heavy-chain human germline framework being used: IGHV1-69 (SEQ ID NO: 1), IGHV3-23 (SEQ ID NO: 2), or IGHV5-51 (SEQ ID NO: 3) in IMGT nomenclature. The three heavy-chain library frameworks are combined with four light-chain library VL kappa  frameworks: A27 (IGKV3-20*01 (SEQ ID NO: 5)), B3 (IGKV4-1*01 (SEQ ID NO: 6)), L6 (IGKV3-11*01 (SEQ ID NO: 7)), and O12 (IGKV1-39*01 (SEQ ID NO: 8)). In the libraries, the Fabs V-regions are completed by the addition of a J-region (FR4) comprising SEQ ID NO: 4 in the heavy chains and SEQ ID NO: 10 in the light chains. The heavy chain CDR3 is of variable length from 7-14 residues. Examples of the complete V-regions for each library are shown in  FIG. 1  and numbered and CDR regions shown according to Kabat. 
     Phage Panning 
     For selection of ATX binding Fabs, the de novo Fab libraries displayed on phage coat protein IX were panned against biotinylated human ATX beta following a published protocol for phage selections with soluble biotinylated antigens (Marks and Bradbury, Antibody Engineering. Humana Press, 248: 161-176, 2004). Briefly, in-house Fab-pIX de novo phage libraries and paramagnetic Streptavidin (SA) beads (Invitrogen, Cat. No. 112.05D) were blocked with 50% (v/v) ChemiBLOCKER (Millipore; Cat. No. 2170) in TBST (Tris buffered saline plus 0.01% Tween). The phage libraries were pre-adsorbed on blocked beads for 30 minutes to remove library components that react directly with the beads. 
     Fab-phage panning was carried out with biotinylated human ATX beta isoform at relatively high concentration of antigen and at low wash stringency during in the first round. The panning parameters were as follows: Round 1: 100 nM antigen, 1 hour incubation at room temperature, 5× washes with TBST followed by 1× wash with TBS; Round 2: 10 nM antigen, 1 hour incubation at room temperature, 10× washes with TBST/lx wash with TBS; Round 3: 1 nM antigen, 16 hour (overnight) incubation at 4° C., 10× washes with TBST/1× wash with TBS. 
     Biotinylated human ATX was added to the pre-absorbed libraries to a final concentration of 100 nM and incubated for 1 hour with gentle rotation. Blocked SA beads were added and incubated for 15 minutes to capture biotinylated ATX with bound phage. The magnetically-captured phage/antigen/bead complex was washed 5 times with 1 ml of TBST and once with 1 ml TBS. Following removal of the final TBS wash, 1 ml of exponentially growing TG1 cells (Stratagene, Cat. No. 200123) was added and incubated at 37° C. for 30 minutes without shaking. Infected bacteria were spread on LB/Agar (1% Glucose/100 μg/ml Carbenicillin) plates (Teknova, Cat. No. L5804) and incubated overnight at 37° C. Bacterial lawns were scraped and glycerol stocks prepared [15% Glycerol/Carbenicillin (100 μg/ml)/2×YT] and stored at −80° C. To prepare phage for second-round panning, 25 ml of 2×YT/Carbenicillin (100 μg/ml) was inoculated with 25 μl of bacterial glycerol stock and grown at 37° C. until an OD600 of roughly 0.5. Helper phage VCSM13 (Stratagene, Cat. No. 200251) was added to the culture at a multiplicity of infection of approximately 10:1 and incubation was carried out for 30 minutes at 37° C. without shaking. The bacteria was spun down and the pellet resuspended in induction media (2×YT/Carb/Kan/IPTG) and grown at 30° C. overnight. Phage was precipitated with 2% PEG/0.25M NaCl (final concentrations) and re-suspended in 2 ml of PBS. First-round phage was stored at 4° C. and used to carry out second-round panning. Antigen concentration was changed to 10 nM and 1 nM for the second-round and third-round panning, respectively. 
     Monoclonal Soluble Fab-His Binding ELISAs 
     Primary ELISA screening of individual clones was performed using secreted soluble Fab-His protein from  E. coli  supernatants. In the pIX phage display vector (pCNTO-Fab-pIX), the Fab CH 1 domain is fused in-frame to the pIX phage-coat protein. Restriction enzyme digestion of the vector with NheI and SpeI results in excision of the pIX gene. Self-ligation/re-circularization of the resulting linearized pIX-minus plasmid leads to the in-frame fusion of a 6×His-tag to the CH1 Fab domain. Purified pIX-minus plasmid was self-ligated/re-circularized and used to transform TG1 cells. Bacterial supernatants, from fresh cultures containing soluble Fab-His protein, were used to carry out binding ELISAs. 
     Fab-His protein prepared as described above was used in a primary binding ELISA screen with biotinylated human ATX beta at a concentration of 5 nM, which should allow the detection of clones with affinities in the nanomolar affinity range. Fabs were captured on black MaxiSorp plates (Nunc, Cat. No. 437111) coated with 1 μg/ml sheep anti-human Fd (CH1) antibody (The Binding Site, Cat. No. PC075). Plates were washed and biotinylated human ATX was added to the captured Fabs at 5 nM. Incubation was carried out for 1 hour at room temperature with gentle shaking. Plates were washed, SA-HRP (Invitrogen, Cat. No. 43-4323) was added and chemiluminescent detection carried out. 
     Clones with binding above background were sequenced and unique clones identified. Table 3 shows the 57 unique Fabs which compositions and the identified germline origin for each pair of variable regions (VH and VL). These clones were identified with binding signal to human ATX at least 6-fold above the background. Table 3 lists the identifier for VH and VL (Peptide ID) and the combination of both (Fab ID) sorted by the Fab ELISA binding data. 
                     TABLE 3                  57 ATX-binding Fab clones                                         Fab       VH-       VL-       Fab ID   Binding   VH   Origin   VL   Origin               F17   2.4E+07   H11   551   L14   L6       F73   1.7E+07   H66   169   L67   O12       F67   8.8E+06   H60   169   L61   O12       F40   8.1E+06   H32   323   L42   L6       F96   5.9E+06   H89   169   IFWL124   O12       F97   5.8E+06   H90   169   IFWL124   O12       F89   5.7E+06   H70   169   L82   A27       F104   5.1E+06   H96   169   IFWL124   O12       F143   4.9E+06   H148   169   H2RL12   O12       F86   4.2E+06   H80   169   L80   O12       F16   3.9E+06   H10   551   L13   O12       F5   3.8E+06   H4   551   L4   L6       F118   2.6E+06   H111   169   L104   A27       F126   2.4E+06   H123   169   L110   A27       F53   2.4E+06   H2   169   L30   L6       F34   2.3E+06   H2   169   L28   L6       F130   2.2E+06   H129   169   L113   A27       F35   2.1E+06   H25   169   L29   L6       F69   2.0E+06   H63   169   L63   L6       F32   2.0E+06   H7   169   PH9L4   O12       F135   2.0E+06   H138   169   L118   A27       F50   1.9E+06   H25   169   L46   L6       F122   1.9E+06   H119   169   L108   A27       F100   1.9E+06   H93   169   PH9L1   A27       F116   1.9E+06   H108   169   L100   O12       F78   1.9E+06   H73   169   L73   A27       F128   1.8E+06   H127   169   L111   A27       F68   1.8E+06   H62   169   L62   A27       F117   1.8E+06   H110   169   L103   O12       F7   1.8E+06   H2   169   L6   L6       F11   1.8E+06   H2   169   L9   L6       F90   1.7E+06   H83   169   L83   A27       F71   1.7E+06   H2   169   L65   L6       F74   1.7E+06   H68   169   L68   L6       F85   1.7E+06   H58   169   L79   A27       F8   1.6E+06   H2   169   L7   L6       F12   1.6E+06   H7   169   L10   L6       F62   1.6E+06   H54   169   GCGL18   O12       F93   1.6E+06   H86   169   L79   A27       F72   1.6E+06   H65   169   PH9L1   A27       F2   1.5E+06   H2   169   L1   L6       F123   1.4E+06   H120   169   PH9L4   O12       F121   1.4E+06   H115   169   L106   L6       F3   1.4E+06   H2   169   L2   L6       F142   1.3E+06   H146   169   L121   O12       F102   1.3E+06   H2   169   L91   L6       F133   1.2E+06   H134   169   L117   A27       F144   1.2E+06   H149   169   L122   A27       F45   1.2E+06   H2   169   L34   L6       F33   1.1E+06   H24   323   L35   O12       F13   1.1E+06   H2   169   L11   L6       F114   1.1E+06   H106   169   L99   L6       F9   1.0E+06   H2   169   L8   L6       F54   9.8E+05   H44   323   IFWL195   O12       F63   9.8E+05   H55   169   L57   L6       F43   9.8E+05   H2   169   L44   L6       F105   9.7E+05   H97   169   L93   A27                    
Sequencing of Fab Clone Hits from Primary ELISA Screen
 
     Individual overnight bacterial cultures corresponding to human ATX binding Fabs identified by the antigen-binding ELISA screen described above were used as a template for PCR amplification of Fab cassettes. Amplification of the Fab DNA (VH, CH, VL, CL) results in a 1.7 kb DNA fragment which is sequenced with multiple forward and reverse primers using standard protocols. Sequence files were analyzed with the SeqScape software (Applied Biosystems). 
     Results 
     Based on the germline origins and their binding activity to human ATX as Fabs, the 12 highest affinity binding Fab from VH germline 1-69, and the top three binding Fabs from VH germline 3-23 and 5-51 were selected for further characterization. All 18 Fabs were converted to mAbs with human IgG1/human Kappa constant regions. Table 4 shows the paring of each recombinant mAb ID and their VH and VL pairing. The 18 VH-VL pairs represented 17 unique VH and 16 unique VL. 
     
       
         
           
               
               
               
               
               
               
               
             
               
                 TABLE 4 
               
               
                   
               
               
                 mAb 
                 FAB 
                 VH SEQ 
                 VH.Peptide 
                 VL SEQ 
                 VL.Peptide 
                   
               
               
                 AA ID 
                 ID 
                 ID 
                 ID 
                 ID 
                 ID 
                 Activity 
               
               
                   
               
             
            
               
                 B1 
                 F5 
                 16 
                 H4 
                 17 
                 L4 
                 Binder 
               
               
                 B2 
                 F16 
                 18 
                 H10 
                 19 
                 L13 
                 Binder 
               
               
                 B3 
                 F17 
                 20 
                 H11 
                 21 
                 L14 
                 Binder 
               
               
                 B4 
                 F53 
                 22 
                 H2 
                 23 
                 L30 
                 Binder 
               
               
                 B5 
                 F34 
                 22 
                 H2 
                 25 
                 L28 
                 Binder 
               
               
                 B6 
                 F73 
                 24 
                 H66 
                 27 
                 L67 
                 Binder &amp; Neutralizer 
               
               
                 B7 
                 F86 
                 26 
                 H80 
                 29 
                 L80 
                 Binder &amp; Neutralizer 
               
               
                 B8 
                 F96 
                 28 
                 H89 
                 31 
                 IFWL124 
                 Binder &amp; Neutralizer 
               
               
                 B9 
                 F89 
                 30 
                 H70 
                 33 
                 L82 
                 Binder &amp; Neutralizer 
               
               
                 B10 
                 F67 
                 32 
                 H60 
                 35 
                 L61 
                 Binder 
               
               
                 B11 
                 F118 
                 34 
                 H111 
                 37 
                 L104 
                 Binder 
               
               
                 B12 
                 F126 
                 36 
                 H123 
                 39 
                 L110 
                 Binder 
               
               
                 B13 
                 F143 
                 38 
                 H148 
                 41 
                 H2RL12 
                 Binder &amp; Neutralizer 
               
               
                 B14 
                 F104 
                 40 
                 H96 
                 31 
                 IFWL124 
                 Binder &amp; Neutralizer 
               
               
                 B15 
                 F33 
                 42 
                 H24 
                 43 
                 L35 
                 Binder 
               
               
                 B16 
                 F40 
                 44 
                 H32 
                 45 
                 L42 
                 Binder 
               
               
                 B17 
                 F54 
                 46 
                 H44 
                 47 
                 IFWL195 
                 Binder 
               
               
                 B18 
                 F97 
                 48 
                 H90 
                 31 
                 IFWL124 
                 Binder &amp; Neutralizer 
               
               
                   
               
            
           
         
       
     
     Example 3 
     Characterization of ATX Binding Mabs 
     One of the objectives of the research was to select high affinity binders to ATX capable of blocking the enzymatic activity of ATX. 
     Of the 57 initially selected ATX-binding Fabs, 18 were cloned into vectors for conversion to full-length human IgG1 Mabs. Routine procedures were used to express and purify the disclosed antibodies. DNA encoding the mAbs molecules were constructed from the Fab clones by fusing VH from Fab with human IgG1 isotype and VL with human Kappa using standard molecule cloning techniques. The heavy and light chains were transiently expressed in HEK 293F cells. The harvested supernatants were purified via Protein A chromatography. 
     Once sufficient material was available, the characterization assays were preformed, including: 
     (1) ability to block lysophoslipase activity as measured using the FS-3 assay,
 
(2) IC50 in the lysophosphocholine cleavage assay,
 
(3) affinity by SPR, and
 
(4) competitive binding analysis or “binning”.
 
     Results 
     The eighteen converted mAbs were first tested in a single-point ATX inhibition assay using the fluorescent substrate, FS-3. The results of this assay, where the measured reaction rate in the presence of each antibody has been normalized to the reaction rate of ATX in the absence of antibody, are shown in  FIG. 2 . Six variants (B6, B8, B9, B13, B14, and B18) showed significant inhibition of substrate hydrolysis by ATX beta isoform and were selected for further characterization. A seventh (B7) which showed lesser inhibition at this concentration, so was also selected. A human IgG1 isotype control antibody showed no inhibition of in this assay. Similar inhibition were observed when B7, B8, and B9 were tested in the same assay using 0.5 μM of either human ATX beta or gamma isoforms, indicating the activity was not isoform specific. 
     Six mAbs (B6, B7, B8, B9, B13, and B14) were selected and tested at varying concentrations in another ATX inhibition assay that measures hydrolysis of the natural ATX substrate, LPC. The IC50 values, were calculated from a four-parameter dose-response model from the data shown in  FIGS. 3 and 4  for each variant tested for inhibition of human and mouse ATX respectively. All variants displayed a dose-dependent inhibition of ATX conversion of LPC to LPA and choline. The small molecule autotaxin inhibitor, 532826, was included as a reference point. The hIgG1 isotype control antibody CNTO 3930 did not inhibit autotaxin in these assays (data not shown). The mAb ATXB18 had not yet been produced when these assays were conducted and was not yet tested in this assay. 
     The five mAbs with the lowest IC50 values in the inhibition assays as well as ATXB3, a non-neutralizing antibody, were tested for their affinity to the human ATX-beta isoform, as measured by surface plasmon resonance. Due to nonspecific binding of the ATX antigen to the chip surface, these experiments had to be conducted in the reverse format, with ATX immobilized on the chip surface (ligand) and our antibodies in solution (analyte). Table 5 lists the measured association rate (ka1, K on ), dissociation rate (kd1, k off ), and dissociation constant (KD1) for each mAb to ATX, calculated using the bivalent analyte model where E stands for base 10. 
     
       
         
           
               
               
               
               
               
             
               
                   
                 TABLE 5 
               
               
                   
                   
               
               
                   
                 mAb IDs 
                 ka1 (1/Ms) 
                 kd1 (1/s) 
                 KD1 (M) 
               
               
                   
                   
               
             
            
               
                   
                 ATXB3 
                 2.12E+05 
                 3.03E−04 
                 7.15E−10 
               
               
                   
                 ATXB6 
                 4.44E+05 
                 2.92E−04 
                 3.29E−10 
               
               
                   
                 ATXB8 
                 2.49E+05 
                 8.83E−04 
                 1.77E−09 
               
               
                   
                 ATXB9 
                 3.37E+03 
                 3.22E−04 
                 4.78E−08 
               
               
                   
                 ATXB13 
                 2.74E+05 
                 3.29E−04 
                 6.00E−10 
               
               
                   
                 ATXB14 
                 7.89E+05 
                 5.83E−04 
                 3.69E−10 
               
               
                   
                 ATXB18 
                 9.49E+05 
                 6.14E−04 
                 6.73E−10 
               
               
                   
                   
               
            
           
         
       
     
     Finally, real-time monitoring of the antibody-ATX biomolecular interaction using Bio-Layer Interferometry on an Octet Red384 instrument was used to determine which of 18 antibodies could bind to ATX simultaneously, and which could not due to epitope overlap, steric hindrance or other reason. A subset of the possible mAb pairings were tested with two goals in mind: (1) to determine whether or not the neutralizing mAbs bound to the same epitope and (2) to identify mAbs that are able to bind ATX simultaneously and, especially, at the same time that a neutralizing mAb was bound. 
     In this assay, the primary mAb was bound to ATX first, and the complex probed for the ability of the secondary mAb to bind. Table 6 shows the compiled results of the mAb pairs tested with a “Y” or “N” indicating whether or not simultaneous binding is possible. An empty box indicates that this pair has not been tested, while a black box denotes self-competition. The neutralizing mAbs exhibiting the highest binding affinity (ATXB6, ATXB8, ATXB13, and ATXB14) were not able to bind ATX simultaneously suggesting that their epitopes may overlap. However, the weaker affinity mAb, ATXB7, was able to bind simultaneously with some of the other neutralizing mAbs and thus binds to a different epitope. In addition, a number of non-neutralizing mAbs were found to occupy different epitopes from those of the neutralizing mAbs, including ATXB2, ATXB3, ATXB10, ATXB15, and ATXB16. ATXB10, ATXB15, and ATXB16 appear to compete for the same epitope. 
     
       
         
           
               
             
               
                 TABLE 6 
               
             
            
               
                   
               
               
                 Screening mAb pairs for simultaneous binding to ATX. 
               
            
           
           
               
               
            
               
                   
                 Secondary mAb 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 Simultaneous 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
                 ATX 
               
               
                 Binding? 
                 B1 
                 B2 
                 B3 
                 B4 
                 B5 
                 B6 
                 B7 
                 B8 
                 B9 
                 B10 
                 B11 
                 B12 
                 B13 
                 B14 
                 B15 
                 B16 
                 B17 
                 B18 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 Primary 
                 ATXB1  
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 mAb 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                   
                 ATXB2  
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 Y 
                   
                   
                   
                 Y 
                   
                   
                 Y 
                   
                   
                   
                   
                 Y 
                 Y 
                   
                   
               
               
                   
               
               
                   
                 ATXB3  
                   
                 Y 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
                 Y 
                 Y 
                 Y 
                   
                 Y 
                   
                   
                 Y 
                   
                 Y 
                 Y 
                   
                   
               
               
                   
               
               
                   
                 ATXB4  
                   
                   
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                   
                 ATXB5  
                   
                   
                   
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                   
                 ATXB6  
                 N 
                 Y 
                 Y 
                 N 
                 N 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 Y 
                 N 
                 N 
                 Y 
                 N 
                 N 
                 N 
                 N 
                 Y 
                 Y 
                 N 
                 N 
               
               
                   
               
               
                   
                 ATXB7  
                   
                 Y 
                 Y 
                   
                   
                 Y 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 Y 
                   
                 Y 
                   
                   
                 Y 
                   
                 Y 
                 Y 
                   
                   
               
               
                   
               
               
                   
                 ATXB8  
                 N 
                 Y 
                 Y 
                 N 
                 N 
                 N 
                 Y 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 N 
                 Y 
                 N 
                 N 
                 N 
                 N 
                 Y 
                 Y 
                 N 
                 N 
               
               
                   
               
               
                   
                 ATXB9  
                   
                   
                   
                   
                   
                   
                   
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                   
                 ATXB10 
                   
                 Y 
                 Y 
                   
                   
                   
                 Y 
                   
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
                   
                   
                 N 
                 N 
                   
                   
               
               
                   
               
               
                   
                 ATXB11 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                   
                 ATXB12 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                   
                 ATXB13 
                 N 
                 Y 
                 Y 
                 N 
                 N 
                 N 
                 Y 
                 N 
                 N 
                 Y 
                 N 
                 N 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 N 
                 Y 
                 Y 
                 N 
                 N 
               
               
                   
               
               
                   
                 ATXB14 
                 N 
                 Y 
                 Y 
                 N 
                 N 
                 N 
                 Y 
                 N 
                 N 
                 Y 
                 N 
                 N 
                 N 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 Y 
                 Y 
                 N 
                 N 
               
               
                   
               
               
                   
                 ATXB15 
                   
                 Y 
                 Y 
                   
                   
                   
                 Y 
                   
                   
                 N 
                   
                   
                   
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 N 
                   
                   
               
               
                   
               
               
                   
                 ATXB16 
                   
                 Y 
                 Y 
                   
                   
                   
                 Y 
                   
                   
                 N 
                   
                   
                   
                   
                 N 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
               
               
                   
                 ATXB17 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                   
               
               
                   
                 ATXB18 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
            
           
         
       
     
     Summary 
     Among the 18 mAbs tested, seven were categorized as neutralizers by demonstrating the ability to inhibit ATX hydrolytic activities. The neutralizers have binding affinity to human ATX in the range of 300 pM to 48 nM. Groups of antibodies with overlapping and non-overlapping epitopes on ATX were also identified (Table 7). 
     
       
         
           
               
               
               
               
             
               
                 TABLE 7 
               
               
                   
               
               
                   
                   
                 When pre-bound to 
                 Cannot bind ATX 
               
               
                   
                   
                 ATX, Mab prevents 
                 when one of 
               
               
                 mAb 
                   
                 binding of specified 
                 specified Mabs 
               
               
                 AA ID 
                 Activity 
                 Mabs to ATX 
                 pre-bound 
               
               
                   
               
             
            
               
                 B1 
                 Binder 
                 No data 
                 B6, B8, B13, B14 
               
               
                 B2 
                 Binder 
                 None as tested 
                 No data 
               
               
                 B3 
                 Binder 
                 None as tested 
                 No data 
               
               
                 B4 
                 Binder 
                 No data 
                 B6, B8, B13, B14 
               
               
                 B5 
                 Binder 
                 No data 
                 B6, B8, B13, B14 
               
               
                 B6 
                 Binder &amp; 
                 B1, B4, B5, B8, B9, 
                 B8, B13, B14 
               
               
                   
                 Neutralizer 
                 B11-14, B17, B18 
               
               
                 B7 
                 Binder &amp; 
                 None 
                 No data 
               
               
                   
                 Neutralizer 
               
               
                 B8 
                 Binder &amp; 
                 B1, B4-6, B9, B11-14, 
                 B6, B8, B13, B14 
               
               
                   
                 Neutralizer 
                 B17, B18 
               
               
                 B9 
                 Binder &amp; 
                 No data 
                 B6, B8, B13, B14 
               
               
                   
                 Neutralizer 
               
               
                 B10 
                 Binder 
                 B15, B16 
                 B15, B16 
               
               
                 B11 
                 Binder 
                 No data 
                 B6, B8, B13, B14 
               
               
                 B12 
                 Binder 
                 No data 
                 B6, B8, B13, B14 
               
               
                 B13 
                 Binder &amp; 
                 B1, B4-6, B8, B9, B11, 
                 B6, B8, B14 
               
               
                   
                 Neutralizer 
                 B12, B14, B17, B18 
               
               
                 B14 
                 Binder &amp; 
                 B1, B4-6, B8, B9, 
                 B6, B8, B13 
               
               
                   
                 Neutralizer 
                 B11-13, B17, B18 
               
               
                 B15 
                 Binder 
                 B10 
                 B10, B16 
               
               
                 B16 
                 Binder 
                 B10 
                 B10, B15 
               
               
                 B17 
                 Binder 
                 No data 
                 B6, B8, B13, B14 
               
               
                 B18 
                 Binder &amp; 
                 No data 
                 B6, B8, B13, B14 
               
               
                   
                 Neutralizer 
               
               
                   
               
            
           
         
       
     
     Example 4 
     Structure Activity Relationship 
     Table 8A-B show the V-region CDR identified for the 57 Fabs clones with a unique pair of variable heavy and light chains (VH and VL). These clones were identified with binding signal to human ATX at least 6-fold above the background. 
     The CDRs of each VH and VL sequence following Kabat CDR definition (Kabat et al., 5th edit. Public Health Service, NIH, Washington, D.C., 1991; Wu and Kabat, J. Exp. Med 132:211-250, 1970) were identified. Each unique CDR sequence is listed by SEQ ID Table 8A (VH CDRs) and 8B (VL CDRs). Note that the VH designated H2 of germline 1-69 origin with H-CDR1=SEQ ID 49, H-CDR2=SEQ ID NO: 53 and H-CDR3=SEQ ID NO: 69 was present 11 times. 
                     TABLE 8A                  Heavy Chain Variable CDR sequences for the 57 Fab clones.                                     Fab ID           CDR-H1   CDR-H2   CDR-H3       (Mab ID)   VH   VH-GL   SEQ ID   SEQ ID   SEQ ID                                             F73 (B6)   H66   1-69   49   53   61       F96 (B8)   H89   1-69   49   53   62       F97 (B18)   H90   1-69   49   53   63       F104 (B14)   H96   1-69   49   54   64       F143 (B13)   H148   1-69   49   53   65       F86 (B7)   H80   1-69   49   53   66       F89 (B9)   H70   1-69   49   55   67       F67 (B10)   H60   1-69   49   53   68       P53 (B4)   H2   1-69   49   53   69       F34 (B5)   H2   1-69   49   53   69       F118 (B11)   H111   1-69   50   53   70       F126 (B12)   H123   1-69   49   53   71       F33 (B15)   H24   3-23   51   56   72       F54 (B17)   H44   3-23   51   56   73       F40 (B16)   H32   3-23   51   57   74       P16 (B2)   H10   5-51   52   58   75       F17 (B3)   H11   5-51   52   58   76       F5 (B1)   H4   5-51   52   58   77       F32   H7   1-69   49   53   78       F116   H108   1-69   49   53   79       F117   H110   1-69   49   53   80       F62   H54   1-69   49   53   81       F123   H120   1-69   49   53   82       F142   H146   1-69   49   53   83       F35   H25   1-69   49   53   84       F69   H63   1-69   49   53   85       F50   H25   1-69   49   53   84       F7   H2   1-69   49   53   69       F11   H2   1-69   49   53   69       F71   H2   1-69   49   53   69       F74   H68   1-69   49   53   86       F8   H2   1-69   49   53   69       F12   H7   1-69   49   53   78       F2   H2   1-69   49   53   69       F121   H115   1-69   49   53   87       F3   H2   1-69   49   53   69       F102   H2   1-69   49   53   69       F45   H2   1-69   49   53   69       F13   H2   1-69   49   53   69       F114   H106   1-69   49   59   88       F9   H2   1-69   49   53   69       F63   H55   1-69   50   53   89       F43   H2   1-69   49   53   69       F130   H129   1-69   49   53   90       F135   H138   1-69   49   53   91       F122   H119   1-69   49   53   92       F100   H93   1-69   49   54   93       F78   H73   1-69   49   53   94       F128   H127   1-69   49   59   95       F68   H62   1-69   50   60   96       F90   H83   1-69   49   53   97       F85   H58   1-69   49   53   98       F93   H86   1-69   49   53   99       F72   H65   1-69   49   53   100       F133   H134   1-69   49   53   101       F144   H149   1-69   50   53   102       F105   H97   1-69   50   53   103                    
Table 8B gives the VL compositions of the 57 Fabs designated by germline origin and individual L-CDR. The VL designated IFWL124 (SEQ ID NO: 31) of O12 origin was found in three Fabs, all of which F96 (Mab B8), F97 (B18), and F104 (B14) were found to neutralize ATX catalytic activity. Three Fabs had also had the germline A27 VL and L-CDRs (PH9L1) and two had the closely related A27 VL designated (L79), however, none of these Fabs were tested for neutralization.
 
     
       
         
           
               
             
               
                 TABLE 8B 
               
             
            
               
                   
               
               
                 VL CDR sequences for the 57 Fab clones. 
               
            
           
           
               
               
               
               
               
               
            
               
                   
                   
                   
                 L-CDR1 
                 L-CDR2 
                 L-CDR3 
               
               
                 Fab ID 
                 VL 
                 VL-GL 
                 SEQ ID 
                 SEQ ID 
                 SEQ ID 
               
               
                   
               
               
                 F73 (B6) 
                 L67 
                 O-12 
                 104 
                 139 
                 155 
               
               
                 F96 (B8) 
                 IFWL124 
                 O-12 
                 105 
                 140 
                 156 
               
               
                 F97 (B18) 
                 IFWL124 
                 O-12 
                 105 
                 140 
                 156 
               
               
                 F104 (B14) 
                 IFWL124 
                 O-12 
                 105 
                 140 
                 156 
               
               
                 F143 (B13) 
                 H2RL12 
                 O-12 
                 106 
                 140 
                 156 
               
               
                 F86 (B7) 
                 L80 
                 O-12 
                 106 
                 141 
                 156 
               
               
                 F89 (B9) 
                 L82 
                 A-27 
                 107 
                 142 
                 157 
               
               
                 F67 (B10) 
                 L61 
                 O-12 
                 108 
                 140 
                 158 
               
               
                 F53 (B4) 
                 L30 
                 L-6 
                 109 
                 143 
                 159 
               
               
                 F34 (B5) 
                 L28 
                 L-6 
                 110 
                 143 
                 160 
               
               
                 F118 (B11) 
                 L104 
                 A-27 
                 111 
                 144 
                 161 
               
               
                 F126 (B12) 
                 L110 
                 A-27 
                 111 
                 144 
                 162 
               
               
                 F33 (B15) 
                 L35 
                 O-12 
                 112 
                 140 
                 156 
               
               
                 F54 (B17) 
                 IFWL195 
                 O-12 
                 113 
                 140 
                 156 
               
               
                 F40 (B16) 
                 L42 
                 L-6 
                 114 
                 145 
                 163 
               
               
                 F16 (B2) 
                 L13 
                 O-12 
                 115 
                 140 
                 156 
               
               
                 F17 (B3) 
                 L14 
                 L-6 
                 114 
                 143 
                 164 
               
               
                 F5 (B1) 
                 L4 
                 L-6 
                 116 
                 146 
                 165 
               
               
                 F32 
                 PH9L4 
                 O-12 
                 108 
                 140 
                 156 
               
               
                 F116 
                 L100 
                 O-12 
                 117 
                 147 
                 166 
               
               
                 F117 
                 L103 
                 O-12 
                 118 
                 140 
                 167 
               
               
                 F62 
                 GCGL18 
                 O-12 
                 108 
                 148 
                 156 
               
               
                 F123 
                 PH9L4 
                 O-12 
                 108 
                 140 
                 156 
               
               
                 F142 
                 L121 
                 O-12 
                 108 
                 140 
                 168 
               
               
                 F35 
                 L29 
                 L-6 
                 110 
                 143 
                 169 
               
               
                 F69 
                 L63 
                 L-6 
                 119 
                 146 
                 170 
               
               
                 F50 
                 L46 
                 L-6 
                 120 
                 149 
                 171 
               
               
                 F7 
                 L6 
                 L-6 
                 121 
                 146 
                 172 
               
               
                 F11 
                 L9 
                 L-6 
                 122 
                 149 
                 173 
               
               
                 F71 
                 L65 
                 L-6 
                 123 
                 150 
                 174 
               
               
                 F74 
                 L68 
                 L-6 
                 124 
                 151 
                 175 
               
               
                 F8 
                 L7 
                 L-6 
                 125 
                 152 
                 176 
               
               
                 F12 
                 L10 
                 L-6 
                 126 
                 152 
                 177 
               
               
                 F2 
                 L1 
                 L-6 
                 127 
                 150 
                 178 
               
               
                 F121 
                 L106 
                 L-6 
                 128 
                 149 
                 179 
               
               
                 F3 
                 L2 
                 L-6 
                 129 
                 152 
                 180 
               
               
                 F102 
                 L91 
                 L-6 
                 130 
                 143 
                 181 
               
               
                 F45 
                 L34 
                 L-6 
                 131 
                 146 
                 182 
               
               
                 F13 
                 L11 
                 L-6 
                 130 
                 145 
                 183 
               
               
                 F114 
                 L99 
                 L-6 
                 132 
                 146 
                 184 
               
               
                 F9 
                 L8 
                 L-6 
                 133 
                 149 
                 185 
               
               
                 F63 
                 L57 
                 L-6 
                 134 
                 143 
                 186 
               
               
                 F43 
                 L44 
                 L-6 
                 110 
                 143 
                 187 
               
               
                 F130 
                 L113 
                 A-27 
                 111 
                 144 
                 188 
               
               
                 F135 
                 L118 
                 A-27 
                 111 
                 144 
                 189 
               
               
                 F122 
                 L108 
                 A-27 
                 111 
                 144 
                 190 
               
               
                 F100 
                 PH9L1 
                 A-27 
                 111 
                 144 
                 191 
               
               
                 F78 
                 L73 
                 A-27 
                 111 
                 144 
                 192 
               
               
                 F128 
                 L111 
                 A-27 
                 111 
                 144 
                 193 
               
               
                 F68 
                 L62 
                 A-27 
                 111 
                 144 
                 194 
               
               
                 F90 
                 L83 
                 A-27 
                 135 
                 153 
                 195 
               
               
                 F85 
                 L79 
                 A-27 
                 111 
                 144 
                 196 
               
               
                 F93 
                 L79 
                 A-27 
                 111 
                 144 
                 196 
               
               
                 F72 
                 PH9L1 
                 A-27 
                 111 
                 144 
                 191 
               
               
                 F133 
                 L117 
                 A-27 
                 136 
                 154 
                 197 
               
               
                 F144 
                 L122 
                 A-27 
                 137 
                 153 
                 198 
               
               
                 F105 
                 L93 
                 A-27 
                 138 
                 142 
                 199 
               
               
                   
               
            
           
         
       
     
     Based on the mAb characterization described in Example 3, the sequences of the 18 mAbs listed in Table 4 are compared with the sequences of the V-regions from all of the 57 unique binding pairs. 
     Among the binding Fab clones:
         of those clones with the highest binding affinity (in relative chemiluminescence units, See Table 3) the heavy chain germline origins were predominantly 1-69 and the light chain origin was IGVK1-39 (O12).   A specific V-region (H2) was found in 13 Fabs each having a unique L6-derived VL.   All seven neutralizing mAbs B6, 7, 8, 9, 13, 14 and 18 (corresponding to Fabs F73, F86, F96, F89, F143, F104, and F97, respectively) are of VH 1-69 and, B6, 7, 8, 13, 14 and 18 have VL of O12 origin. All but B9 have the motif YGX 5 X 6 DY where X 5  is D or F, and X 6  is F or L in H-CDR3 (residues 103-108 of SEQ ID NO: 200).
           Mab B9 (Fab F89) bound ATX with high affinity and is a neutralizer, is from VH germline 1-69 but does not have the identified motif (YGX 5 X 6 DY where X 5  is D or F, and X 6  is F or L in H-CDR3 (residues 103-108 of SEQ ID NO: 200)) in H-CDR3 and the VL is from A27.   Mab B10 (Fab F67) was one of the top three binders to ATX, has VH germline 1-69 frameworks and VL germline IGVK1-39 (O-12) frameworks, however, it has a longer H-CDR3 which does not contain the formula (YGX 5 X 6 DY where X 5  is D or F, and X 6  is F or L in H-CDR3 (residues 103-108 of SEQ ID NO: 200)) and it is also not a neutralizer.   Mab B3 (F17) contains H-CDR3 PYG T FDY (SEQ ID NO: 76), is of VH5-51 and VL L6 origin and is not a neutralizer.   
           For the six neutralizing Mabs having a VL of O12 origin, three have the identical VL (IFW124, SEQ ID NO: 31) and five have the identical L-CDR3 (QQSYSTPL, SEQ ID NO: 156).       

     Therefore, a consensus sequence for an ATX neutralizing human IGHV1-69 germline derived VH comprising FR1-CDR1-FR2-CDR2-FR3-CDR3 can be represented as SEQ ID NO: 200: 
                    QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLEWMG                 GI X 1 P X 2 FG X 3  X 4 NYAQKFQG RVTITADESTSTAYMELSSLRSED               TAVYYCAR DLYIYG   X 5  X 6 DY              
wherein  X 1  is I or S, X 2  is I or Y, X 3  is N or T, X 4  is A or T,  X 5  is D or
 
     F and X 5  is F or L. 
     As six of seven VL derive from the IGVK1-39 (012) germline (L67, L80, IFWL124, or L82, SEQ ID NO: 27, 29, 31, or 33), a consensus sequence for an ATX neutralizing human gene derived VL comprising FR1-CDR1-FR2-CDR2-FR3-CDR3 can be represented as SEQ ID NO: 201: 
                    DIQMTQSPSSLSASVGDRVTITC RASQSI X 1  X 2 WLN WYQQKPGKAPKL               LIY X 3 ASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYX 4                     X 5 P X 6 T              
wherein  X 1    is A, D or G;  X 2    is G or K; and  X 3    is A or T; and  X 4    is S or T;  X 5    is T or Y; and  X 6    is I or L.
 
     Based on these analyses, an antibody or antibody fragment comprising binding domains derived from the human germline VH 1-69 combined with human germline VLkappa O12 has a high likelihood of specific, high affinity binding to ATX. In particular embodiment, an antibody or antibody fragment comprising one of the four variants of SEQ ID NO: 200 and a human germline VL kappa O12-derived would be expected to bind ATX and be capable of neutralizing ATX catalytic activity. 
     
       
         
           
               
            
               
                   
               
               
                 Sequence Table 
               
            
           
           
               
               
               
            
               
                 SEQ ID 
                   
                   
               
               
                 NO: 
                 Description 
                 SEQUENCE AND FEATURES 
               
               
                   
               
            
           
           
               
               
               
            
               
                 1 
                 Human IGHV1- 
                 QVQLVQSGAE VKKPGSSVKV SCKASGGTFS  SYX   1   IS WVRQA 
               
               
                   
                 69*01 
                 PGQGLEWMG X   2    IX   3   X   4   X   5   X   6   GTANY AQKFQG RVTI TADESTSTAY 
               
               
                   
                   
                 MELSSLRSED TAVYYCAR 
               
               
                   
                   
                 Where X 1  is A or G, X 2  is G or W, X 3  may be I 
               
               
                   
                   
                 or S, X 4  may be P or A, X 5  may be I or Y and X 6   
               
               
                   
                   
                 may be F or N. 
               
               
                   
               
               
                 2 
                 Human IGHV3- 
                 EVQLLESGGG LVQPGGSLRL SCAASGFTFS  X   1   YX   2   MX   3 WVRQA 
               
               
                   
                 23*01 
                   PGKGLEWVS X 4    IX   5   X   6   X   7   GX   8   STYY   A DSVKGRFTI SRDNSKNTLY 
               
               
                   
                   
                 LQMNSLRAED TAVYYCAK 
               
               
                   
                   
                 Where X 1  may be S, D, N, or T; X 2  may be A, G, 
               
               
                   
                   
                 or W; X 3  may be S or H; X 4  may by V, A, N or G; 
               
               
                   
                   
                 X 5  may be S, N, K or W; X 6  may be Y, S, G, or Q; 
               
               
                   
                   
                 X 7  may be S or D; and X 8  may be S or G 
               
               
                   
               
               
                 3 
                 Human IGHV5- 
                 EVQLVQSGAE VKKPGESLKI SCKGSGYSFT  X   1   YWIX   2 WVRQM 
               
               
                   
                 51*01 
                 PGKGLEWMG X   3   IX   4   PX   5   DSX   6   TRY SPSFQG QVTI SADKSISTAY 
               
               
                   
                   
                 LQWSSLKASD TAMYYCAR 
               
               
                   
                   
                 Where X 1  may be S, N, or T; X 2  may be S or G; X 3   
               
               
                   
                   
                 may be I or R; X 4  may by D or Y; X 5  may be G or 
               
               
                   
                   
                 S; X 6  may be D or Y 
               
               
                   
               
               
                 4 
                 Human JH 
                 WGQGTLVTVSS 
               
               
                   
               
               
                 5 
                 Human IGKV1- 
                 DIQMTQSPSS LSASVGDRVT ITCRAS QSI X   1   X   2   X   3   LN WYQQKP 
               
               
                   
                 39*01 (O12) 
                 GKAPKLLIY X   4    ASSLQS GVPS RFSGSGSGTD FTLTISSLQP 
               
               
                   
                   
                 EDFATYYC 
               
               
                   
                   
                 Where X 1  may be A, D, N, S, or R; X 2  may be D, 
               
               
                   
                   
                 G, K, N, or S; X 3  may be A, D, F, H, N, S, W, 
               
               
                   
                   
                 V, or Y; X 4  may be A, D, F, G, K, N, T, or Y. 
               
               
                   
               
               
                 6 
                 IGKV3-11 (L6) 
                 EIVLTQSPAT LSLSPGERAT LSCRAS QSV X   1   X   2   X   3   LA WYQQKP 
               
               
                   
                   
                 GQAPRLLIY X   4   ASNRAT GIPA RFSGSGSGTD FTLTISSLEP 
               
               
                   
                   
                 EDFAVYYC 
               
               
                   
                   
                 Where X 1  may be A, D, N, R or S; X 2  may be D, 
               
               
                   
                   
                 K, N, or S; X 3  may be A, D, F, H, N, S, W, or 
               
               
                   
                   
                 Y; X 4  may be A, D, K, G, F, T or N. 
               
               
                   
               
               
                 7 
                 Human IGKV3- 
                 EIVLTQSPGT LSLSPGERAT LSC X   1   X   2   X   3   X   4   SVS SSYLA WYQQK 
               
               
                   
                 20 (A27) 
                 PGQAPRLLIY  X   5   ASSRAT GIP DRFSGSGSGT DFTLTISRLE 
               
               
                   
                   
                 PEDFAVYYC 
               
               
                   
                   
                 Where X 1  may be D, N, S, R or T; X 2  may be N, S, 
               
               
                   
                   
                 or R; X 3  may be A, D, H, N, S, or R; X 4  may be 
               
               
                   
                   
                 E, F, H, K, Q, S, or Y; X 5  may be A, D, G, or 
               
               
                   
                   
                 S. 
               
               
                   
               
               
                 8 
                 Human IGKV4- 
                 DIVMTQSPDS LAVSLGERAT INC KSSQSVL   X   1   SSNNX   2   NX   3   LA   
               
               
                   
                 1*01 (B3) 
                 WYQQKPGQPP KLLIY X   4   ASTR   ES GVPDRFSG SGSGTDFTLT 
               
               
                   
                   
                 ISSLQAEDVA VYYC 
               
               
                   
                   
                 Where X 1  may be A, F, H, S, or Y; X 2  may be E, 
               
               
                   
                   
                 K, N, or T; X 3  may be A, D, F, H, N, S, W, or 
               
               
                   
                   
                 Y; X 4  may be A, D, S, W or Y. 
               
               
                   
               
               
                 9 
                 L-CDR3 
                 QQX 1 X 2 X 3 X 4 PX 5 T 
               
               
                   
                 formula 
                 Where X 1  may be A, D, F, H, P, S, or Y; X 2  may 
               
               
                   
                   
                 be D, E, G, H, I, K, N, R, T or Y; X 3  may be 
               
               
                   
                   
                 D, G, H, K, N, S, T, or R; X 4  may be F, I, L, 
               
               
                   
                   
                 N, R, W or Y as defined in Table 2. 
               
               
                   
               
               
                 10 
                 JK4 
                 FGQGTKVEIK 
               
               
                   
               
               
                 11 
                 human ATX 
                 MARRSSFQSCQIISLFTFAVGVNICLGFTAHRIKRAEGWEEGPPTV 
               
               
                   
                 isoform beta, 
                 LSDSPWTNISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDE 
               
               
                   
                 863 aa 
                 LCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVC 
               
               
                   
                   
                 KGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSK 
               
               
                   
                   
                 VMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVG 
               
               
                   
                   
                 NSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFW 
               
               
                   
                   
                 SVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFG 
               
               
                   
                   
                 PEMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCD 
               
               
                   
                   
                 RTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIANLTC 
               
               
                   
                   
                 KKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHVARKPLD 
               
               
                   
                   
                 VYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGSTFKYKTKVPPFEN 
               
               
                   
                   
                 IELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEVTRPN 
               
               
                   
                   
                 YPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEERHLL 
               
               
                   
                   
                 YGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSS 
               
               
                   
                   
                 VPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLSSSP 
               
               
                   
                   
                 EAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNGVNVISG 
               
               
                   
                   
                 PIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPA 
               
               
                   
                   
                 DKCDGPLSVSSFILPHRPDNEESCNSSEDESKWVEELMKMHTARVR 
               
               
                   
                   
                 DIEHLTSLDFFRKTSRSYPEILTLKTYLHTYESEI 
               
               
                   
               
               
                 12 
                 human ATX 
                 MARRSSFQSCQIISLFTFAVGVNICLGFTAHRIKRAEGWEEGPPTV 
               
               
                   
                 isoform alpha, 
                 LSDSPWTNISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDE 
               
               
                   
                 915 aa 
                 LCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVC 
               
               
                   
                   
                 KGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSK 
               
               
                   
                   
                 VMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVG 
               
               
                   
                   
                 NSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFW 
               
               
                   
                   
                 SVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFG 
               
               
                   
                   
                 PEESSYGSPFTPAKRPKRKVAPKRRQERPVAPPKKRRRKIHRMDHY 
               
               
                   
                   
                 AAETRQDKMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGM 
               
               
                   
                   
                 EDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAI 
               
               
                   
                   
                 IANLTCKKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHV 
               
               
                   
                   
                 ARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGSTFKYKTK 
               
               
                   
                   
                 VPPFENIELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPE 
               
               
                   
                   
                 EVTRPNYPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGST 
               
               
                   
                   
                 EERHLLYGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSK 
               
               
                   
                   
                 QAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPP 
               
               
                   
                   
                 YLSSSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNG 
               
               
                   
                   
                 VNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCL 
               
               
                   
                   
                 DFTQPADKCDGPLSVSSFILPHRPDNEESCNSSEDESKWVEELMKM 
               
               
                   
                   
                 HTARVRDIEHLTSLDFFRKTSRSYPEILTLKTYLHTYESEI 
               
               
                   
               
               
                 13 
                 human ATX 
                 MARRSSFQSCQIISLFTFAVGVNICLGFTAHRIKRAEGWEEGPPTV 
               
               
                   
                 isoform 
                 LSDSPWTNISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDE 
               
               
                   
                 gamma, 888 aa 
                 LCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVC 
               
               
                   
                   
                 KGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSK 
               
               
                   
                   
                 VMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVG 
               
               
                   
                   
                 NSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFW 
               
               
                   
                   
                 SVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFG 
               
               
                   
                   
                 PEMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCD 
               
               
                   
                   
                 RTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIANLTC 
               
               
                   
                   
                 KKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHVARKPLD 
               
               
                   
                   
                 VYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGSTFKYKTKVPPFEN 
               
               
                   
                   
                 IELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEVTRPN 
               
               
                   
                   
                 YPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEAETRK 
               
               
                   
                   
                 X1RGX2RNENKENINGNFEPRKERHLLYGRPAVLYRTRYDILYHTD 
               
               
                   
                   
                 FESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSF 
               
               
                   
                   
                 SQNCLAYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAF 
               
               
                   
                   
                 KRVWNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQ 
               
               
                   
                   
                 YVEGSSIPVPTHYYSIITSCLDFTQPADKCDGPLSVSSFILPHRPD 
               
               
                   
                   
                 NEESCNSSEDESKWVEELMKMHTARVRDIEHLTSLDFFRKTSRSYP 
               
               
                   
                   
                 EILTLKTYLHTYESEI 
               
               
                   
               
               
                 14 
                   Mus  spps. ATX 
                 MARQGCFGSYQVISLFTFAIGVNLCLGFTASRIKRAEWDEGPPTVL 
               
               
                   
                   
                 SDSPWTNTSGSCKGRCFELQEVGPPDCRCDNLCKSYSSCCHDFDEL 
               
               
                   
                   
                 CLKTARGWECTKDRCGEVRNEENACHCSEDCLSRGDCCTNYQVVCK 
               
               
                   
                   
                 GESHWVDDDCEEIRVPECPAGFVRPPLIIFSVDGFRASYMKKGSKV 
               
               
                   
                   
                 MPNIEKLRSCGTHAPYMRPVYPTKTFPNLYTLATGLYPESHGIVGN 
               
               
                   
                   
                 SMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVRAGTFFWS 
               
               
                   
                   
                 VSIPHERRILTILQWLSLPDNERPSVYAFYSEQPDFSGHKYGPFGP 
               
               
                   
                   
                 EMTNPLREIDKTVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCDR 
               
               
                   
                   
                 TEFLSNYLTNVDDITLVPGTLGRIRPKIPNNLKYDPKAIIANLTCK 
               
               
                   
                   
                 KPDQHFKPYMKQHLPKRLHYANNRRIEDLHLLVERRWHVARKPLDV 
               
               
                   
                   
                 YKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGPTFKYRTKVPPFENI 
               
               
                   
                   
                 ELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTLPEEVSRPNY 
               
               
                   
                   
                 PGIMYLQSDFDLGCTCDDKVEPKNKLEELNKRLHTKGSTEERHLLY 
               
               
                   
                   
                 GRPAVLYRTSYDILYHTDFESGYSEIFLMPLWTSYTISKQAEVSSI 
               
               
                   
                   
                 PEHLTNCVRPDVRVSPGFSQNCLAYKNDKQMSYGFLFPPYLSSSPE 
               
               
                   
                   
                 AKYDAFLVTNMVPMYPAFKRVWTYFQRVLVKKYASERNGVNVISGP 
               
               
                   
                   
                 IFDYNYNGLRDIEDEIKQYVEGSSIPVPTHYYSIITSCLDFTQPAD 
               
               
                   
                   
                 KCDGPLSVSSFILPHRPDNDESCNSSEDESKWVEELMKMHTARVRD 
               
               
                   
                   
                 IEHLTGLDFYRKTSRSYSEILTLKTYLHTYESEI 
               
               
                   
               
               
                 15 
                 Purification 
                 GSHHHHHH 
               
               
                   
                 Tag 
                 fused at the N-terminal of position 49 of ATX 
               
               
                   
                   
                 proteins 
               
               
                   
               
               
                 16 
                 H4 in B1 
                 EVQLVQSGAEVKKPGESLKISCKGSGYSFT SYWIG WVRQMPGKGLE 
               
               
                   
                   
                 WMG IIYPGDSDTRYSPSFQG QVTISADKSISTAYLQWSSLKASDTA 
               
               
                   
                   
                 MYYCAR NWSEALYVVFDY   
               
               
                   
               
               
                 17 
                 L4 in B1 
                 EIVLTQSPATLSLSPGERATLSC RASQSVANFLA WYQQKPGQAPRL 
               
               
                   
                   
                 LIY YASNRAT GIPARFSGSGSGTDFTLTISSLEPEDFAVYYC QQYF   
               
               
                   
                   
                 
                   SAPFT 
                 
               
               
                   
               
               
                 18 
                 H10 in B2 
                 EVQLVQSGAEVKKPGESLKISCKGSGYSFT SYWIG WVRQMPGKGLE 
               
               
                   
                   
                 WMG IIYPGDSDTRYSPSFQG QVTISADKSISTAYLQWSSLKASDTA 
               
               
                   
                   
                 MYYCAR GLADFWYFDY   
               
               
                   
               
               
                 19 
                 L13 in B2 
                 DIQMTQSPSSLSASVGDRVTITC RASQSIDVWLN WYQQKPGKAPKL 
               
               
                   
                   
                 LIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSY   
               
               
                   
                   
                 
                   STPLT 
                 
               
               
                   
               
               
                 20 
                 H11 in B3 
                 EVQLVQSGAEVKKPGESLKISCKGSGYSFT SYWIG WVRQMPGKGLE 
               
               
                   
                   
                 WMG IIYPGDSDTRYSPSFQG QVTISADKSISTAYLQWSSLKASDTA 
               
               
                   
                   
                 MYYCAR PYGTFDY   
               
               
                   
               
               
                 21 
                 L14 in B3 
                 EIVLTQSPATLSLSPGERATLSC RASQSVADSLA WYQQKPGQAPRL 
               
               
                   
                   
                 LIY KASNRAT GIPARFSGSGSGTDFTLTISSLEPEDFAVYYC QQSN   
               
               
                   
                   
                 
                   GWPRT 
                 
               
               
                   
               
               
                 22 
                 H2 in B4 and 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLE 
               
               
                   
                 B5 
                 WMG GIIPIFGTANYAQKFQG RVTITADESTSTAYMELSSLRSEDTA 
               
               
                   
                   
                 VYYCAR DDLPLGRLDY   
               
               
                   
               
               
                 23 
                 L30 in B4 
                 EIVLTQSPATLSLSPGERATLSC RASQSVNKHLA WYQQKPGQAPRL 
               
               
                   
                   
                 LIY KASNRAT GIPARFSGSGSGTDFTLTISSLEPEDFAVYYC QQGI   
               
               
                   
                   
                 
                   RAPYT 
                 
               
               
                   
               
               
                 24 
                 H66 in B6 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLE 
               
               
                   
                   
                 WMG GIIPIFGTANYAQKFQG RVTITADESTSTAYMELSSLRSEDTA 
               
               
                   
                   
                 VYYCAR DLYIYGDLDY   
               
               
                   
               
               
                 25 
                 L28 in B5 
                 EIVLTQSPATLSLSPGERATLSC RASQSVAKFLA WYQQKPGQAPRL 
               
               
                   
                   
                 LIY KASNRAT GIPARFSGSGSGTDFTLTISSLEPEDFAVYYC QQFN   
               
               
                   
                   
                   SAPIT F 
               
               
                   
               
               
                 26 
                 H80 in B7 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLE 
               
               
                   
                   
                 WMG GIIPIFGTANYAQKFQG RVTITADESTSTAYMELSSLRSEDTA 
               
               
                   
                   
                 VYYCAR PIGTGYYGFFDY   
               
               
                   
               
               
                 27 
                 L67 in B6 
                 DIQMTQSPSSLSASVGDRVTITC RASQSIGGWLN WYQQKPGKAPKL 
               
               
                   
                   
                 LIY TASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSY   
               
               
                   
                   
                 
                   TYPIT 
                 
               
               
                   
               
               
                 28 
                 H89 in B8 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLE 
               
               
                   
                   
                 WMG GIIPIFGTANYAQKFQG RVTITADESTSTAYMELSSLRSEDTA 
               
               
                   
                   
                 VYYCAR DSSAYGDFDY   
               
               
                   
               
               
                 29 
                 L80 in B7 
                 DIQMTQSPSSLSASVGDRVTITC RASQSIAKWLN WYQQKPGKAPKL 
               
               
                   
                   
                 LIY FASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSY   
               
               
                   
                   
                 
                   STPLT 
                 
               
               
                   
               
               
                 30 
                 H70 in B9 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLE 
               
               
                   
                   
                 WMG GISPYFGNANYAQKFQG RVTITADESTSTAYMELSSLRSEDTA 
               
               
                   
                   
                 VYYCAR YGDFGGNVFTEFDY   
               
               
                   
               
               
                 31 
                 VL-IFWL124 in 
                 DIQMTQSPSSLSASVGDRVTITC RASQSIDGWLN WYQQKPGKAPKL 
               
               
                   
                 B8, B14, and 
                 LIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSY   
               
               
                   
                 B18 
                 
                   STPLT 
                 
               
               
                   
               
               
                 32 
                 H60 in B10 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLE 
               
               
                   
                   
                 WMG GIIPIFGTANYAQKFQG RVTITADESTSTAYMELSSLRSEDTA 
               
               
                   
                   
                 VYYCAR IARYARGYMHTFDY   
               
               
                   
               
               
                 33 
                 L82 in B9 
                 EIVLTQSPGTLSLSPGERATLSC RASQSVNNSDLA WYQQKPGQAPR 
               
               
                   
                   
                 LLIY TASSRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQA   
               
               
                   
                   
                 
                   TTVPLT 
                 
               
               
                   
               
               
                 34 
                 H111 in B11 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYGIS WVRQAPGQGLE 
               
               
                   
                   
                 WMG GIIPIFGTANYAQKFQG RVTITADESTSTAYMELSSLRSEDTA 
               
               
                   
                   
                 VYYCAR DDLPLGMLDY   
               
               
                   
               
               
                 35 
                 L61 in B10 
                 DIQMTQSPSSLSASVGDRVTITC RASQSISSYLN WYQQKPGKAPKL 
               
               
                   
                   
                 LIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQHL   
               
               
                   
                   
                 
                   SIPIT 
                 
               
               
                   
               
               
                 36 
                 H123 in B12 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLE 
               
               
                   
                   
                 WMG GIIPIFGTANYAQKFQG RVTITADESTSTAYMELSSLRSEDTA 
               
               
                   
                   
                 VYYCAR DRYYFTVLDY   
               
               
                   
               
               
                 37 
                 L104 in B11 
                 EIVLTQSPGTLSLSPGERATLSC RASQSVSSSYLA WYQQKPGQAPR 
               
               
                   
                   
                 LLIY GASSRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQY   
               
               
                   
                   
                 
                   TAFPLT 
                 
               
               
                   
               
               
                 38 
                 H148 in B13 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLE 
               
               
                   
                   
                 WMG GIIPIFGTANYAQKFQG RVTITADESTSTAYMELSSLRSEDTA 
               
               
                   
                   
                 VYYCAR DFSVYGDFDY   
               
               
                   
               
               
                 39 
                 L110 in B12 
                 EIVLTQSPGTLSLSPGERATLSC RASQSVSSSYLA WYQQKPGQAPR 
               
               
                   
                   
                 LLIY GASSRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQA   
               
               
                   
                   
                 
                   TAFPLT 
                 
               
               
                   
               
               
                 40 
                 H96 in B14 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLE 
               
               
                   
                   
                 WMG GIIPIFGNTNYAQKFQG RVTITADESTSTAYMELSSLRSEDTA 
               
               
                   
                   
                 VYYCAR DISGYGDLDY   
               
               
                   
               
               
                 41 
                 H2RL12 in B13 
                 DIQMTQSPSSLSASVGDRVTITC RASQSIAKWLN WYQQKPGKAPKL 
               
               
                   
                   
                 LIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSY   
               
               
                   
                   
                 
                   STPLT 
                 
               
               
                   
               
               
                 42 
                 H153 in B15 
                 EVQL VQ SGGGLVQPGGSLRLSCAASGFTFS SYAMS WVRQAPGKGLE 
               
               
                   
                   
                 WVS AISGSGGSTYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTA 
               
               
                   
                   
                 VYYCAK NAWEGAMLDY   
               
               
                   
               
               
                 43 
                 L35 in B15 
                 DIQMTQSPSSLSASVGDRVTITC RASQSIHNWLN WYQQKPGKAPKL 
               
               
                   
                   
                 LIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSY   
               
               
                   
                   
                 
                   STPLT 
                 
               
               
                   
               
               
                 44 
                 H154 in B16 
                 EVQL VQ SGGGLVQPGGSLRLSCAASGFTFS SYAMS WVRQAPGKGLE 
               
               
                   
                   
                 WVS VINSDGSSIYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTA 
               
               
                   
                   
                 VYYCAK LEAIDYAWGFDY   
               
               
                   
               
               
                 45 
                 L42 in B16 
                 EIVLTQSPATLSLSPGERATLSC RASQSVADSLA WYQQKPGQAPRL 
               
               
                   
                   
                 LIY NASNRAT GIPARFSGSGSGTDFTLTISSLEPEDFAVYYC QQSF   
               
               
                   
                   
                 
                   HWPLT 
                 
               
               
                   
               
               
                 46 
                 H155 in B17 
                 EVQL VQ SGGGLVQPGGSLRLSCAASGFTFS SYAMS WVRQAPGKGLE 
               
               
                   
                   
                 WVS AISGSGGSTYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTA 
               
               
                   
                   
                 VYYCAK DVKGSATLDY   
               
               
                   
               
               
                 47 
                 IFWL195 in 
                 DIQMTQSPSSLSASVGDRVTITC RASQSIANWLN WYQQKPGKAPKL 
               
               
                   
                 B17 
                 LIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSY   
               
               
                   
                   
                 
                   STPLT 
                 
               
               
                   
               
               
                 48 
                 H90 in B18 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLE 
               
               
                   
                   
                 WMG GIIPIFGTANYAQKFQG RVTITADESTSTAYMELSSLRSEDTA 
               
               
                   
                   
                 VYYCAR DASTYGDLDY   
               
               
                   
               
               
                 49 
                 CDR-H1 
                 SYAIS 
               
               
                   
               
               
                 50 
                 CDR-H1 
                 SYGIS 
               
               
                   
               
               
                 51 
                 CDR-H1 
                 SYAMS 
               
               
                   
               
               
                 52 
                 CDR-H1 
                 SYWIG 
               
               
                   
               
               
                 53 
                 CDR-H2 
                 GIIPIFGTANYAQKFQG 
               
               
                   
               
               
                 54 
                 CDR-H2 
                 GIIPIFGNTNYAQKFQG 
               
               
                   
               
               
                 55 
                 CDR-H2 
                 GISPYFGTANYAQKFQG 
               
               
                   
               
               
                 56 
                 CDR-H2 
                 AISGSGGSTYYADSVKG 
               
               
                   
               
               
                 57 
                 CDR-H2 
                 VINSDGSSIYYADSVKG 
               
               
                   
               
               
                 58 
                 CDR-H2 
                 IIYPGDSDTRYSPSFQG 
               
               
                   
               
               
                 59 
                 CDR-H2 
                 GIIPIFGNANYAQKFQG 
               
               
                   
               
               
                 60 
                 CDR-H2 
                 GIIPIFGTTNYAQKFQG 
               
               
                   
               
               
                 61 
                 CDR-H3 
                 DLYIYGDLDY 
               
               
                   
               
               
                 62 
                 CDR-H3 
                 DSSAYGDFDY 
               
               
                   
               
               
                 63 
                 CDR-H3 
                 DASTYGDLDY 
               
               
                   
               
               
                 64 
                 CDR-H3 
                 DISGYGDLDY 
               
               
                   
               
               
                 65 
                 CDR-H3 
                 DFSVYGDFDY 
               
               
                   
               
               
                 66 
                 CDR-H3 
                 PIGTGYYGFFDY 
               
               
                   
               
               
                 67 
                 CDR-H3 
                 YGDFGGNVFTEFDY 
               
               
                   
               
               
                 68 
                 CDR-H3 
                 IARYARGYMHTFDY 
               
               
                   
               
               
                 69 
                 CDR-H3 
                 DDLPLGRLDY 
               
               
                   
               
               
                 70 
                 CDR-H3 
                 DDLPLGMLDY 
               
               
                   
               
               
                 71 
                 CDR-H3 
                 DRYYFTVLDY 
               
               
                   
               
               
                 72 
                 CDR-H3 
                 KNAWEGAMLDY 
               
               
                   
               
               
                 73 
                 CDR-H3 
                 KDVKGSATLDY 
               
               
                   
               
               
                 74 
                 CDR-H3 
                 KLEAIDYAWGFDY 
               
               
                   
               
               
                 75 
                 CDR-H3 
                 GLADFWYFDY 
               
               
                   
               
               
                 76 
                 CDR-H3 
                 PYGTFDY 
               
               
                   
               
               
                 77 
                 CDR-H3 
                 NWSEALYVVFDY 
               
               
                   
               
               
                 78 
                 CDR-H3 
                 DDVALGRLDY 
               
               
                   
               
               
                 79 
                 CDR-H3 
                 SDLNNVSTVLDY 
               
               
                   
               
               
                 80 
                 CDR-H3 
                 ADANQLSGYLDY 
               
               
                   
               
               
                 81 
                 CDR-H3 
                 EDVALGRLDY 
               
               
                   
               
               
                 82 
                 CDR-H3 
                 HDVNSLWAYFDY 
               
               
                   
               
               
                 83 
                 CDR-H3 
                 GDYNAIYYALDY 
               
               
                   
               
               
                 84 
                 CDR-H3 
                 DDLALGRLDY 
               
               
                   
               
               
                 85 
                 CDR-H3 
                 DDDVNSLASYPLDY 
               
               
                   
               
               
                 86 
                 CDR-H3 
                 DGDVNSVYSSGLDY 
               
               
                   
               
               
                 87 
                 CDR-H3 
                 GDANALYDYFDY 
               
               
                   
               
               
                 88 
                 CDR-H3 
                 DDWLSHFDY 
               
               
                   
               
               
                 89 
                 CDR-H3 
                 RDGNYLHVDHFDY 
               
               
                   
               
               
                 90 
                 CDR-H3 
                 DHGYAYYSAFDY 
               
               
                   
               
               
                 91 
                 CDR-H3 
                 DFLSQFSWLDY 
               
               
                   
               
               
                 92 
                 CDR-H3 
                 DGVTTYDYFDY 
               
               
                   
               
               
                 93 
                 CDR-H3 
                 HYLPDATLDY 
               
               
                   
               
               
                 94 
                 CDR-H3 
                 GTFTYDFLDY 
               
               
                   
               
               
                 95 
                 CDR-H3 
                 GFVNFSRLDY 
               
               
                   
               
               
                 96 
                 CDR-H3 
                 DWWVTDILDY 
               
               
                   
               
               
                 97 
                 CDR-H3 
                 GEANEVYPGLDY 
               
               
                   
               
               
                 98 
                 CDR-H3 
                 DLYGIDIYYALDY 
               
               
                   
               
               
                 99 
                 CDR-H3 
                 DTFWFTVFDY 
               
               
                   
               
               
                 100 
                 CDR-H3 
                 GDANSIYPLFDY 
               
               
                   
               
               
                 101 
                 CDR-H3 
                 GADSNAVRLVGFDY 
               
               
                   
               
               
                 102 
                 CDR-H3 
                 EDVNYISTYSEFDY 
               
               
                   
               
               
                 103 
                 CDR-H3 
                 GDDNEVIYHLDY 
               
               
                   
               
               
                 104 
                 CDR-L1 
                 RASQSIGGWLN 
               
               
                   
               
               
                 105 
                 CDR-L1 
                 RASQSIDGWLN 
               
               
                   
               
               
                 106 
                 CDR-L1 
                 RASQSIAKWLN 
               
               
                   
               
               
                 107 
                 CDR-L1 
                 RASQSVNNSDLA 
               
               
                   
               
               
                 108 
                 CDR-L1 
                 RASQSISSYLN 
               
               
                   
               
               
                 109 
                 CDR-L1 
                 RASQSVNKHLA 
               
               
                   
               
               
                 110 
                 CDR-L1 
                 RASQSVAKFLA 
               
               
                   
               
               
                 111 
                 CDR-L1 
                 RASQSVSSSYLA 
               
               
                   
               
               
                 112 
                 CDR-L1 
                 RASQSIHNWLN 
               
               
                   
               
               
                 113 
                 CDR-L1 
                 RASQSIANWLN 
               
               
                   
               
               
                 114 
                 CDR-L1 
                 RASQSVADSLA 
               
               
                   
               
               
                 115 
                 CDR-L1 
                 RASQSIDVWLN 
               
               
                   
               
               
                 116 
                 CDR-L1 
                 RASQSVANFLA 
               
               
                   
               
               
                 117 
                 CDR-L1 
                 RASQSIGKVLN 
               
               
                   
               
               
                 118 
                 CDR-L1 
                 RASQSIGRSLN 
               
               
                   
               
               
                 119 
                 CDR-L1 
                 RASQSVSKALA 
               
               
                   
               
               
                 120 
                 CDR-L1 
                 RASQSVSSFLA 
               
               
                   
               
               
                 121 
                 CDR-L1 
                 RASQSVNSWLA 
               
               
                   
               
               
                 122 
                 CDR-L1 
                 RASQSVADFLA 
               
               
                   
               
               
                 123 
                 CDR-L1 
                 RASQSVSDYLA 
               
               
                   
               
               
                 124 
                 CDR-L1 
                 RASQSVNKFLA 
               
               
                   
               
               
                 125 
                 CDR-L1 
                 RASQSVRDWLA 
               
               
                   
               
               
                 126 
                 CDR-L1 
                 RASQSVRKYLA 
               
               
                   
               
               
                 127 
                 CDR-L1 
                 RASQSVRNFLA 
               
               
                   
               
               
                 128 
                 CDR-L1 
                 RASQSVSNWLA 
               
               
                   
               
               
                 129 
                 CDR-L1 
                 RASQSVNNFLA 
               
               
                   
               
               
                 130 
                 CDR-L1 
                 RASQSVADWLA 
               
               
                   
               
               
                 131 
                 CDR-L1 
                 RASQSVSSWLA 
               
               
                   
               
               
                 132 
                 CDR-L1 
                 RASQSVADYLA 
               
               
                   
               
               
                 133 
                 CDR-L1 
                 RASQSVAKDLA 
               
               
                   
               
               
                 134 
                 CDR-L1 
                 RASQSVASALA 
               
               
                   
               
               
                 135 
                 CDR-L1 
                 RASQSVSKSALA 
               
               
                   
               
               
                 136 
                 CDR-L1 
                 RASQSVAYSSLA 
               
               
                   
               
               
                 137 
                 CDR-L1 
                 RASQSVRKSGLA 
               
               
                   
               
               
                 138 
                 CDR-L1 
                 RASQSVAKSDLA 
               
               
                   
               
               
                 139 
                 CDR-L2 
                 TASSLQS 
               
               
                   
               
               
                 140 
                 CDR-L2 
                 AASSLQS 
               
               
                   
               
               
                 141 
                 CDR-L2 
                 FASSLQS 
               
               
                   
               
               
                 142 
                 CDR-L2 
                 TASSRAT 
               
               
                   
               
               
                 143 
                 CDR-L2 
                 KASNRAT 
               
               
                   
               
               
                 144 
                 CDR-L2 
                 GASSRAT 
               
               
                   
               
               
                 145 
                 CDR-L2 
                 NASNRAT 
               
               
                   
               
               
                 146 
                 CDR-L2 
                 YASNRAT 
               
               
                   
               
               
                 147 
                 CDR-L2 
                 GASSLQS 
               
               
                   
               
               
                 148 
                 CDR-L2 
                 KASSLQS 
               
               
                   
               
               
                 149 
                 CDR-L2 
                 TASNRAT 
               
               
                   
               
               
                 150 
                 CDR-L2 
                 DASNRAT 
               
               
                   
               
               
                 151 
                 CDR-L2 
                 FASNRAT 
               
               
                   
               
               
                 152 
                 CDR-L2 
                 GASHRAT 
               
               
                   
               
               
                 153 
                 CDR-L2 
                 NASSRAT 
               
               
                   
               
               
                 154 
                 CDR-L2 
                 AASSRAT 
               
               
                   
               
               
                 155 
                 CDR-L3 
                 QQSYTYPIT 
               
               
                   
               
               
                 156 
                 CDR-L3 
                 QQSYSTPLT 
               
               
                   
               
               
                 157 
                 CDR-L3 
                 QQATTVPLT 
               
               
                   
               
               
                 158 
                 CDR-L3 
                 QQHLSIPIT 
               
               
                   
               
               
                 159 
                 CDR-L3 
                 QQGIRAPYT 
               
               
                   
               
               
                 160 
                 CDR-L3 
                 QQFNSAPIT 
               
               
                   
               
               
                 161 
                 CDR-L3 
                 QQYTAFPLT 
               
               
                   
               
               
                 162 
                 CDR-L3 
                 QQATAFPLT 
               
               
                   
               
               
                 163 
                 CDR-L3 
                 QQSFHNPLT 
               
               
                   
               
               
                 164 
                 CDR-L3 
                 QQSHGWPRT 
               
               
                   
               
               
                 165 
                 CDR-L3 
                 QQYFSAPFT 
               
               
                   
               
               
                 166 
                 CDR-L3 
                 QQPISTPLT 
               
               
                   
               
               
                 167 
                 CDR-L3 
                 QQPFDYPFT 
               
               
                   
               
               
                 168 
                 CDR-L3 
                 QQPISFPYT 
               
               
                   
               
               
                 169 
                 CDR-L3 
                 QQGHGWPPT 
               
               
                   
               
               
                 170 
                 CDR-L3 
                 QQYKMAPRT 
               
               
                   
               
               
                 171 
                 CDR-L3 
                 QQSHRAPWT 
               
               
                   
               
               
                 172 
                 CDR-L3 
                 QQGHPWPFT 
               
               
                   
               
               
                 173 
                 CDR-L3 
                 QQGSTAPYT 
               
               
                   
               
               
                 174 
                 CDR-L3 
                 QQGSDAPLT 
               
               
                   
               
               
                 175 
                 CDR-L3 
                 QQYHHAPFT 
               
               
                   
               
               
                 176 
                 CDR-L3 
                 QQGDGWPWT 
               
               
                   
               
               
                 177 
                 CDR-L3 
                 QQGDTAPI 
               
               
                   
               
               
                 178 
                 CDR-L3 
                 QQGYRAPIT 
               
               
                   
               
               
                 179 
                 CDR-L3 
                 QQRYTAPWT 
               
               
                   
               
               
                 180 
                 CDR-L3 
                 QQFKGAPLT 
               
               
                   
               
               
                 181 
                 CDR-L3 
                 QQSFRWPLT 
               
               
                   
               
               
                 182 
                 CDR-L3 
                 QQFKGWPFT 
               
               
                   
               
               
                 183 
                 CDR-L3 
                 QQYIRWPIT 
               
               
                   
               
               
                 184 
                 CDR-L3 
                 QQYISAPLT 
               
               
                   
               
               
                 185 
                 CDR-L3 
                 QQGINWPFT 
               
               
                   
               
               
                 186 
                 CDR-L3 
                 QQGGNWPWT 
               
               
                   
               
               
                 187 
                 CDR-L3 
                 QQYSTWPFT 
               
               
                   
               
               
                 188 
                 CDR-L3 
                 QQSSRDPWT 
               
               
                   
               
               
                 189 
                 CDR-L3 
                 QQSSGFPLT 
               
               
                   
               
               
                 190 
                 CDR-L3 
                 QQSSRYPWT 
               
               
                   
               
               
                 191 
                 CDR-L3 
                 QQYGSSPLT 
               
               
                   
               
               
                 192 
                 CDR-L3 
                 QQSSRFPWT 
               
               
                   
               
               
                 193 
                 CDR-L3 
                 QQDSAFPWT 
               
               
                   
               
               
                 194 
                 CDR-L3 
                 QQSNTNPLT 
               
               
                   
               
               
                 195 
                 CDR-L3 
                 QQSNKDPLT 
               
               
                   
               
               
                 196 
                 CDR-L3 
                 QQSNTLPLT 
               
               
                   
               
               
                 197 
                 CDR-L3 
                 QQSNTPPLT 
               
               
                   
               
               
                 198 
                 CDR-L3 
                 QQATKPPLT 
               
               
                   
               
               
                 199 
                 CDR-L3 
                 QQDYGYPLT 
               
               
                   
               
               
                 200 
                 consensus 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLE 
               
               
                   
                 sequence for 
                 WMGGI X1P X2FG 
               
               
                   
                 an ATX 
                 X3X4NYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDL 
               
               
                   
                 neutralizing 
                 YIYG X5 X6DY 
               
               
                   
                 human IGHV1- 
                 wherein X1 is I or S, X2 is I or Y, X3 is N or T, 
               
               
                   
                 69 germline 
                 X4 is A or T, X5 is D or F and X5 is F or L 
               
               
                   
                 derived VH 
                   
               
               
                   
               
               
                 201 
                 consensus 
                   
               
               
                   
                 sequence for 
                 DIQMTQSPSSLSASVGDRVTITC RASQSI   
               
               
                   
                 an ATX 
                   X 1 X 2 WLN WYQQKPGKAPKLLIY X 3 ASSLQS GVPSRFSGSGSGTDFTL 
               
               
                   
                 neutralizing 
                 TISSLQPEDFATYYC QQSY X 4  X 5 P X 6 T   
               
               
                   
                 human gene 
                 wherein  X 1    is A, D or G;  X 2    is G or K; and  X 3    is 
               
               
                   
                 derived 
                 A or T; and  X 4    is S or T;  X 5    is T or Y; and  X 6     
               
               
                   
                 IGKV1-39 
                 is I or L 
               
               
                   
                 (O12) VL 
                   
               
               
                   
               
               
                 202 
                 
                   Homo sapiens 
                 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLE 
               
               
                   
                 IGHV1-69 
                 WMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTA 
               
               
                   
                 germline gene 
                 VYYCARWGQGTLVTVSS 
               
               
                   
                 with joining 
                   
               
               
                   
                 JH 
                   
               
               
                   
               
               
                 203 
                   Homo   sapiens   
                 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLE 
               
               
                   
                 IGHV3-23 
                 WVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTA 
               
               
                   
                 germline gene 
                 VYYCAKWGQGTLVTVSS 
               
               
                   
                 with joining 
                   
               
               
                   
                 JH 
                   
               
               
                   
               
               
                 204 
                   Homo   sapiens   
                 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLE 
               
               
                   
                 IGHV5-51 
                 WMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTA 
               
               
                   
                 germline gene 
                 MYYCARWGQGTLVTVSS 
               
               
                   
                 with joining 
                   
               
               
                   
                 JH 
                   
               
               
                   
               
               
                 205 
                 IGKV3-20 
                 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPR 
               
               
                   
                 germline gene 
                 LLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQY 
               
               
                   
                 with joining 
                 GSSPLTFGQGTKVEIK 
               
               
                   
                 JK 
                   
               
               
                   
               
               
                 206 
                   Homo   sapiens   
                 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKP 
               
               
                   
                 IGKV4-1 
                 GQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVY 
               
               
                   
                 germline gene 
                 YCQQYYSTPLTFGQGTKVEIK 
               
               
                   
                 with joining 
                   
               
               
                   
                 JK 
                   
               
               
                   
               
               
                 207 
                   Homo   sapiens   
                 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRL 
               
               
                   
                 IGKV3-11 
                 LIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRS 
               
               
                   
                 germline gene 
                 NWPLTFGQGTKVEIK 
               
               
                   
                 with joining 
                   
               
               
                   
                 JK 
                   
               
               
                   
               
               
                 208 
                   Homo   sapiens   
                 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKL 
               
               
                   
                 IGKV1-39 
                 LIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSY 
               
               
                   
                 germline gene 
                 STPLTFGQGTKVEIK 
               
               
                   
                 with joining 
                   
               
               
                   
                 JK